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The acquisition of genomic alterations is a defining feature of human cancers.  Many 
cancer chemotherapies rely upon an apoptotic pathway to eradicate cells containing those 
alterations. One such alteration is the epigenetic methylation of cytosine in DNA, which occurs 
at CpG sites in dense clusters of CpG dinucleotide repeats within the gene promoter region. The 
maintenance of appropriate methylation levels of DNA is necessary during normal DNA 
replication. Disruption of correct and appropriate methylation patterns leads to DNA associated 
with transcriptional silencing. Cytosine methylation is catalyzed by DNA methyltransferase 
enzymes (DNMTs), which transfer a methyl group from S-adenosylmethionine to the 5-position 
of cytosine to yield 5-methylcytosine.  While there are four main classes of DNMTs, DNMT1 is 
the most abundant methylase responsible for maintaining gene expression patterns following 
cell division. Therapeutics that can inhibit DNMT1 can reactivate genes silenced by 
hypermethylation, therefore, the design and development of novel DNMT1 inhibitors is a 
worthy goal, especially since the silenced genes remain intact and functional. This dissertation 
outlines a systematic approach taken to the successful design and testing of isoindolinone-
based DNMT1 inhibitors. Three synthetic routes were employed to create the inhibitors, the 
routes include an Ugi-IMDAF reaction, a multiple step scheme using homothallic acid as a 
starting point, and utilizing convertible isocyanides.  The best compound synthesized and tested 
was 78, which has a % DNMT1 activity of 7.31 ± 0.98 and a calculated Ki
’ value of 18 ± 3 μM.  
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 THE USE OF SMALL MOLECULE DRUGS TO INHIBIT EPIGENETIC Chapter 1
ALTERATIONS OF DNA. 
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1.1 Epigenetics 
 
The term epigenetics was initially conceived to describe the causal mechanisms that 
bring about different phenotypes in fruit flies.1 Today, this classification is expanding to include 
a variety of biological processes that includes heritable changes in gene expression that occur 
independent of alterations of DNA bases. The recent publications by Holliday, Jablonka et al. 
describe the mechanism by which epigenetic modifications occur including chromatin 
remodeling, DNA methylation, RNA transcription, microRNA synthesis, and prion formation.2,3  
The modulation of epigenetic modification involving DNA methylation is the major focus of this 
dissertation. 
1.2 Chromatin and DNA Methylation 
 
 The major function of chromatin is to tightly package eukaryotic DNA into a small 
enough bundle to fit within the confines of the nucleus.4 The dense packaging is vital to 
preserve an entire genome within one cell; however, this compactness can also be an obstacle. 
If the DNA is packaged too tightly, it is not readily accessible and vital functions including 
transcription, replication, repair, and recombination are no longer feasible.  Consequently, 
there must be a balance between genome packaging and genome accessibility. This concept is 
the basis for either enabling transcription factors to bind to a targeted DNA sequence, or 
altogether preventing access to that particular sequence. In this way, epigenetic information is 
regulated by chromatin packaging and chromatin modifications that involve histones and DNA. 
 Histones and nonhistone proteins are the major structural units of chromatin. Histones 
are abundant within the cell and five distinct histones are recognized as structurally vital to 
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chromatin composition: H1, H2A, H2B, H3, and H4.5 All five are positively charged, arginine or 
lysine rich proteins that interact via ionic bonds with the negatively charged phosphate 
backbone of DNA. Two copies of each histone protein H2A, H2B, H3, and H4 assemble to form 
octameric core structures, and the DNA helix winds itself about these core octamers, creating 
nucleosomes.  Luger et al. deduced the structure of this DNA wrapped histone core (Figure 1.1 
and Figure 1.2).5 The core octamer of each histone has landmarks that guide 147 base pairs of 
DNA in a left-handed superhelical conformation that makes 1.6 turns about the core. The fifth 
histone protein, H1, is a linker protein that binds nucleosomes together resulting in 29-43 base 
pairs of DNA between each nucleosome.  
 
 
Figure 1.1. Head-on view of DNA wrapped around a histone core. Image adapted from work by 
Luger et al.5  
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Figure 1.2. Side view of DNA wrapped around a histone core. Image adapted from work by 
Luger et al.5 
 
 DNA is often targeted for epigenetic modifications, which includes methylation.6,7 This 
DNA methylation is an epigenetic marker that occurs at the 5-position of cytosine in a CpG 
dinucleotide (Figure 1.3).8  DNA methylation is associated with transcriptional silencing of genes 
linked in pathogenesis of many diseases including cancer.9-11 Methylation is catalyzed by DNA 
methyltransferases (DNMTs) and the majority of CpG dinucleotides are located in CpG islands, 
which occupy about 50% - 60% of gene promoters.12,13 
 
Figure 1.3. The Cytosine 5-position is the site where DNA methylation occurs.  
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DNA methylation is vital for regulating embryonic development and is required for 
chromosomal stability.14 When the promotor regions are subjected to methylation, the 
corresponding gene is repressed, because they are not recognized by transcription factors.15   A 
failure to maintain the epigenetic markers and DNA methylation patterns is associated with 
under and over expression of certain proteins, which can lead to cancer.16  As a whole, the 
epigenetic modifications have been associated with virtually all types of cancer.17-23    Unlike 
genetic mutations, epigenetic modifications are reversible and the DNA sequence never 
changed.24,25 For these reasons, DNA methylation is an exciting target for therapeutics. 
 
1.3 DNA methyltransferases (DNMTs) 
 
DNMTs are divided into two classes based on their preferred substrate and function 
(Figure 1.4).26,27  In Homo sapiens, DNMTs share common features, specifically a regulating N-
terminal domain and a catalytic C-terminal domain.28 There are ten sequence motifs in the 
catalytic domain (I to X) that act as binding sites for the substrate S-adenosyl-L-methionine 
(SAM) (Figure 1.4).29 The N-terminal region of DNMTs binds DNA and has protein recognition 
domains to guide the DNMTs to the nucleus and chromatin , thus creating a link between 
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chromatin and DNA methylation.28  
 
Figure 1.4. Schematic representations of the human DNMT1, TRDMT1, and DNMT3s.29   
 
DNMT1 is the most abundant of the DNMTs, and has a higher affinity for 
hemimethylated DNA than unmethylated DNA compared to other DNA methyltransferases.30-32 
DNMT1 typically intercedes after DNA replication to methylate the newly formed strand and 
achieves methylation via two mechanisms: (i) through direct interaction with the replication 
fork and (ii) as a partner of ubiquitin with PHD and ring finger domains 1 (UHRF1), which 
recognizes and binds hemimethylated DNA and recruits DNMT1 to help propagate DNA 
methylation patterns (Figure 1.5).33,34 DNMT1’s main function is to copy patterns of CG 
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methylation onto the newly synthesized DNA strand.35-37 The cytosine to be methylated is 
flipped out into the catalytic pocket and the methyl group of SAM is transferred to the 5-
position (Figure 1.6).28  After the CpG is fully methylated, DNMT1 moves along the newly 
synthesized DNA strand and methylates where needed.  
 
Figure 1.5.  DNMT1 interacting with the replication fork of DNA synthesis.  
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Figure 1.6.  Schematic representation of the catalytic site of the DNMTs showing the targeted 
cytidine (blue), the SAM substrate (red), and catalytic thiolate (green). 
 
The general mechanism of DNA methylation is uniform for all methylating enzymes; the 
enzymes catalyze the transfer of a methyl group from SAM to the targeted cytosine.38 The 5-
position of the cytosine is poorly reactive, and prevents direct methylation, for this reason, 
DNMTs undergo a covalent catalytic reaction (Figure 1.7).39  The targeted cytosine enters the 
catalytic site, the thiolate of the cysteine performs a nucleophilic attack on the 6-position of the 
cytosine.  This reaction leads to the formation of an enamine.  A nucleophilic attack of the 
enamine on the SAM is followed by deprotonation of the C5 by a base, releasing a molecule of 
S-adenosyl-L-homocysteine (SAH). The new methyl group causes a steric hindrance in favor of a 
Catalytic 
Cysteine 
of DNMT 
SAM 
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β-elimination allowing the enzyme to be reused. The newly methylated DNA strand is then 
released from the catalytic pocket along with SAH. 40   
 
Figure 1.7.  Catalytic mechanism of C5-DNA methylation showing the targeted cytidine (blue), 
the methyl group (red), and the catalytic thiolate (green). 
  
The preservation of DNA methylation patterns is not always correct and possesses an 
error frequency of around 5% per CpG, allowing cells some flexibility for changing methylation 
patterns.41 DNMT3a and DNMT3b are frequently utilized to assist DNMT1 in the maintenance 
of methylation profiles during replication.42  Both DNMT3a and DNMT3b are present in smaller 
quantities in human cells, and bind to both unmethylated and hemimethylated CpG sites.43 The 
roles of these two enzymes are de novo methylation. DNMT3L is a cofactor for DNMT3a, as 
DNMT3L possesses no catalytic motif.44   
 Aberrant DNA methylation patterns are extensively observed in numerous cancers 
(Figure 1.8).45,46 Hypermethylation of gene promoter regions silences those particular segments 
of DNA, causing that strand to be completely unrecognizable by RNA polymerase II. The ability 
to reverse DNA methylation offers interesting opportunities in the realm of treatment options.  
By creating targeted inhibitors of DNMT (DNMTi), there is significant potential to allow the 
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transcription factors to work unhindered, inducing the reprogramming of cancerous cells within 
the body.47 
 
Figure 1.8.  Representation of methylation patterns found in normal and cancerous cells. 
  
1.4 DNMT inhibitors 
 
Given the importance of DNMT1 in various diseases including cancer, a number of 
inhibitors were designed and are continually being optimized to exploit the mechanism of 
methylation within the conserved residues of the catalytic pocket of DNMT1.   Two classes of 
inhibitors will be discussed further: nucleoside-like inhibitors and non-nucleoside inhibitors.  
 Nucleoside-like inhibitors are cytosine analogs that cannot inhibit DNMT1 directly, but 
instead become incorporated into the DNA (Figure 1.9).48 Once in the DNA, the cytosine analogs 
are recognized by the DNMTs and undergo similar reactions as normal cytosines, specifically a 
covalent intermediate forms between the catalytic cysteine of the enzyme and the 6-postion of 
11 
 
the cytosine analogs.  From this juncture the reaction deviates from real cytosine interactions, 
since the β-elimination reaction cannot occur due to the presence of a nitrogen atom in the 5-
position of the analogs.49 As a result, a covalent irreversible complex, known as a “suicide 
inhibitor” remains.  The disadvantage of using these types of inhibitors is that most need to be 
chemically modified within the body to be incorporated in to DNA.  
5-Azacytidine, 4, was described more than 50 years ago, but its demethylation activity 
was discovered in 1980 as the result of its ability to influence cellular differentiation.50,51 5-
Azacytidine is an antitumor agent for the treatment of myelodysplastic syndrome.52 5-
Azacytidine is a ribose nucleoside and thus needs to be modified to a deoxyribonucleotide to be 
incorporated into DNA. However, before all 5-azacytidine is converted, a small portion of it is 
incorporated into RNA, which affects a variety of RNA functions including ribosome 
biogenesis.53 5-Aza-2’-deoxycytidine (Decitabine, 5), is a deoxyribose analogue that does not 
need to be modified and can be more directly incorporated into DNA.  Therefore, Decitabine 
shows greater inhibition of DNA methylation and antitumor activity in experimental models.54  
Decitabine has activity in myeloid malignancies including myelodysplastic syndrome, acute 
myelogenous leukemia, and chronic myelogenous leukemia. 55,56 However, decitabine has 
substantial toxic effects, in particular myelosuppression.57   A study performed by Cheng et al. 
showed that orally administered 2-Pyrimidone-1-β-D-riboside (Zebularine, 6) caused detectable 
demethylation and inhibits tumor growth in mice. 58,59 
The use of nucleoside-like drugs is associated with increased incidence of bone marrow 
suppression, including neutropenia and thrombocytopenia.25,60-62 Because nucleoside-like 
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inhibitors are inherently cytotoxic, interest has been on the rise to find non-nucleoside 
inhibitors, whose mechanism does not include incorporation into DNA. Non-nucleoside 
inhibitors interact with DNMTs directly, and can be reversible.  The reversibility feature lowers 
the toxic effects associated with nucleoside-like inhibitors.63  
Discovering therapies that selectively inhibit DNMT1, reverse hypermethylated 
phenotypes, revitalize the normal cell cycle, and reactivate the apoptosis mechanism, are vital 
research targets. Advancement in therapies is a necessity due to the stubborn nature and poor 
prognosis of cancer caused by hypermethylation and epigenetic silencing of tumor suppressor 
genes.64 Synthesizing small molecule drugs that both target and modify epigenetic responses in 
cancer cells have significant advantages over classical chemotherapy as the target genes remain 
intact and are simply silenced due to an epigenetic modification.65   
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Figure 1.9.  Nucleoside-like inhibitors of DNMTs.  This type of inhibitor creates an irreversible 
complex with DNA. 
   
At present, several drugs have made it through clinical trials and are permitted for 
human use.52 Unfortunately, most of the active compounds currently in use are nucleoside-like 
inhibitors that incorporate into the DNA and covalently bind DNMT1, thereby lowering the 
active concentration of DNMT1 in the cell. Reducing the availability of DNMT consequently 
lowers gene methylation, reactivates tumor suppressor genes, and returns normal apoptotic 
responses.62,66  These inhibitors are non-specific, thus affecting healthy cells as well. The high 
levels of toxicity and short half-lives of these drugs have seriously hindered their utility.67  
14 
 
Non-nucleoside inhibitors have been investigated in an attempt to overcome the 
problems with cytosine analogs (Figure 1.10). These studies highlight a number of approaches 
to identify new lead compounds.68-73 Epigallocatechin-3-gallate, 7, is a natural product isolated 
from green tea. Epigallocatechin-3-gallate has been shown to inhibit methyltransferase activity 
in protein extracts and human cancer cell lines.74 Yoo et al. showed that epigallocatechin-3-
gallate degrades in the body to form hydrogen peroxide and the oxidation of DNA 
methyltransferases might contribute to the inhibition of DNA methylation and to its cytotoxicity 
in human cell lines. 25,75 Psammaplin A, 11, is a natural products isolated from a marine 
sponge.76  Although it has been shown that psammaplin exerts strong cytotoxic effects in 
human tumor cell lines and limits grow rates, DNMT inhibition was not followed by DNA 
demethylation and re-expression of tumor suppressor genes. 77 Procainamide, 10, and 
hydralazine, 9, are drugs recently used that are being repurposed in an attempt to generate 
clinically useful DNMT inhibitors.77 Hydralazine is currently in phase II trials for breast cancer 
and phase III trials for cervical and ovarian cancer.  The phthalimide protected tryptophan 
derivative RG108, 8, was identified in a fragment-based virtual screening campaign and 
represents a success of rational drug design.78-80 A major pitfall for these compounds remains 
the toxicity and lack of potency when tested in animal models.81,82  
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Figure 1.10. Non-nucleoside analogs that are used as inhibitors of epigenetic methylation 
catalyzed by DNMT1. 
 
In summary, there are several DNMT inhibitors known, but the high levels of toxicity, 
lack of specificity, and chemical instability hinder the use of them.81 Therefore, it is of great 
need to design and synthesize novel drugs that can specifically target DNMTs.  
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 BIOLOGICAL EVALUATION OF INHIBITORS USING A Chapter 2
RADIOACTIVITY-BASED ASSAY 
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2.1 Introduction  
 
Recent studies have shown DNMT1 as a therapeutic target in diagnosis and treatment of 
various types of cancer since aberrant DNMT1 activity usually occurs before other signs of 
malignancy.83-87 The activity of DNMT1, at a cellular level, has to be screened in order to gain an 
insight into the regulation of methylation and determine therapeutic strategies.88-90 
Conventional assays used to screen global methylation include enzyme-linked immunosorbent 
assay (ELISA), fluorescence-based, and radioactivity-based.  Even though all three techniques 
prove to be useful, they are not without limitations. The following sections will give examples 
and explain each assay.  
2.2 Enzyme-linked immunosorbent assays (ELISA) 
 
There are several commercially available kits, all enzyme-linked immunosorbent assay 
(ELISA) based, that provide a way to assess DNA methylation levels.  ELISA procedures are 
typically uniform for all kits (Figure 2.1). Briefly, the DNA is captured on a ELISA plate, and the 
methylated DNA is detected through sequential incubation steps of: a primary antibody raised 
against 5-methylcytosine, a labelled secondary antibody, and a colorimetric/fluorometric 
detection method.91 ELISA allows for the evaluation of major changes in global methylation 
levels, meaning region-specific DNA methylation cannot be analyzed.  
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Figure 2.1. Schematic of ELISA procedure.  
 
An example of this type of assay is seen in the work produced by Kremer et al. in which 
they quantify genome-wide DNA methylation patterns.92 In Kremer’s work, DNA was applied to 
a microtiter plate and incubated overnight.  The plate wells were then washed twice with 200 
μL of TBS followed by anti-5-methylcytosine mouse antibody and incubated for 1 h.  The plate 
was then washed and incubated with a conjugated goat anti-mouse polyclonal antibody for 1 h. 
After three more washing steps, substrate reagent was added and incubated for 20 minutes 
and the reaction stopped by the addition of H2SO4.  The finished assay plate was then loaded 
onto a plate reader and the absorption read at 450 nm.  
A second example of implementing this assay type is seen in the work of Karaca et al.93 
Total DNMT activity was measured using an EpiQuik DNA Methyltransferase activity assay. 
Karaca added 3 μL of isolated DNA extract to each well of an ELISA plate. The plate was washed 
and incubated with primary and secondary antibodies followed by a developing solution.  The 
finished assay plate was then loaded onto a plate reader and absorption read at 450 nm. 
19 
 
It is easy to see that this assay type requires great attention to detail.  There is a large 
number of time-consuming steps making this assay slow.  In addition, attention needs to be 
given to the amount of freeze thaw cycles the cells undergo because it has been shown over 
periods of time that significant variability of signal arises.94,95 Overall, this assay was not chosen 
to assess the DNMT1 activity with our inhibitors because of the time consuming procedures.  
 
2.3 Fluorescence-based assays 
 
2.3.1 Direct florescent-based assay 
 
In this assay a fluorophore and quencher are attached to either single-stranded DNA or 
double-stranded DNA which organize into hairpin probes.96 Typically, the fluorophores get 
energy from light and when the quenchers are in close proximity, the quenchers absorb the 
energy and emit as heat, thus preventing the fluorophores from fluorescing.97 The basic form of 
this assay type is shown in detail by Wood et al (Figure 2.2).98 
Wood’s assay couples the use of a methylation sensitive restriction endonuclease with 
the protection of cleavage of a break light oligonucleotide.  A break light is a single-stranded 
oligonucleotide, that forms a hairpin loop consisting of a fluorophore at the 5’ terminus and a 
quencher at the 3’ terminus.99 This structure places the fluorophore and quencher close in 
space, promoting efficient quenching (Figure 2.2). Once the hairpin probe is methylated by 
DNMT1, the restriction endonuclease GlaI cleaves the probe at the methylated sites, creating 
single-stranded DNA and a short double-stranded DNA segment.  The cleavage causes the 
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melting of short double-stranded DNA segment and separation of the fluorophore and 
quencher resulting in increased fluorescence.   
 
Figure 2.2. Fluorescent-based assay detailed by Wood et al.98 The fluorescence of the 
hemimethylated oligonucleotide 1 is quenched by a dabcyl group (black dot). DNMT1 
methylates the oligonucleotide to yield 2, which is then cleaved by GlaI, separating the 
fluorophore (pink dot) from the quencher and leading to an increased fluorescence 3. 
 
When the assay described by Wood et al.98 was investigated as a potential screening 
technique for inhibitory drugs, GlaI was sensitive to the antitumor drugs concentrations at 100 
μM, resulting in the methylated sequence remaining whole.  This drawback limits the versatility 
of the assay in clinical settings.  In addition, GlaI is expensive to use, and large quantities are 
needed per assay.   
2.3.2 Amplified fluorescent-based assay    
 
Xing et al.  reported a way of detecting DNA methylation by using substrate hairpin 
probes with methylation sequences in the stems and the fluorophore (FAM)/quencher (BHQ) 
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labelled hairpin, reporting probes (FQ), and utilizing exonuclease III (Exo III). 100 The signal is 
amplified by Exo III-assisted recycling (Figure 2.3).101 Figure 2.3Once the DNA has successfully 
been methylated and cleaved by Dpn 1, single-stranded DNA is released.  The released DNA 
strands then hybridize to the 3’ terminus of the FQ probe. Exo III then binds to the blunt 3’ 
terminus of FQ and degrades the probe, releasing FAM.  The benefit of using Exo III is that it 
only digests from the 3’ terminus of double-stranded DNA with blunt or receding ends.102 The 
single-stranded DNA produced from the substrate hairpin probes is unaffected during Exo III 
treatment.  Consequently, the single-stranded DNA is available for the next step of 
hybridization and digestion, thus creating a recycling mechanism.   Fluorescence from FAM is 
amplified after several rounds of incubation with Exo III, thus allowing for sensitive detection of 
DNA methylation activity. The detection sensitivity is much better than direct fluorescent-based 
assays, and can detect as low as 0.01 U.mL-1.96,100 The procedure outlined by Xing et al. is a 
labor intensive, multistep fluorescent assay that requires expensive reagents making this 
technique not ideal for every laboratory.  
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Figure 2.3 Schematic representation of assay for methylation activity based on exonuclease 
recycling. Adenine (green dot) methylated adenine (red dot).  
 
2.3.3 Conclusion 
 
Fluorescence-based assays involve the absorption of light that excites fluorophores to 
promote electrons from ground states to excited states.  The advantages to fluorescent-based 
assays are their straightforwardness in the detection process and high sensitivity.103 The 
disadvantage of this technique is neither DNA nor methylated DNA is intrinsically fluorescent.  
The fluorescence-based assays require a fluorescence generation mechanism so that the 
methylation event can be detected by a fluorimeter. The high cost associated with specific 
instrumentation and specific antibodies makes this assay type not ideal for every laboratory.  
Fluorescence-based assays can be broadly classified into direct and amplified assays.  Generally, 
the amplified assay out performs its unamplified counterpart. The downside to the amplified 
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assay is the high cost and time-consuming procedures.  Due to the high cost and time intensive 
procedures, this assay type was not chosen to assess the DNMT1 activity with our inhibitors.    
 
2.4 Radioactivity-based assays 
 
The aim of this type of assay is to monitor the incorporation of [3H]-methyl groups into 
DNA. Briefly, DNMT1 transfers from [methyl-3H] SAM the radiolabeled methyl group into the 
DNA. Any unreacted [methyl-3H] SAM can be separated from the radiolabeled DNA using gel 
filtration,104 filter-binding,105 or thin layer chromatography.106  The DNA, now with radiolabeled 
methyl groups can be quantified by liquid scintillation.   
An example of this type of assay is seen in the work produced by Gros et al. when utilizing 
a [methyl-3H] SAM along with a scintillation proximity assay (SPA).107 In SPA, the scintillant is 
fixed onto microplate,108 or incorporated into beads.109 The methylation step of the assay was 
done in homogeneous phase and incorporated tritiated methyl groups into a biotinylated DNA 
substrate. The reaction was then transferred and quenched in a streptavidin-coated microplate 
containing streptavidin-coated beads (Figure 2.4). The problem with this type of radioactivity 
assay is there are many steps that need to be followed. The large amounts of incubation, and 
wash steps make this technique time consuming.  
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Figure 2.4 DNMT radioactivity-based assay detailed in work by Gros et al. Biotin (gray circle), 
tritium atoms (stars) lightning bolt represents ability for tritium atoms to excite scintillator.   
 
The assay used to analyze the DNMT1 activity in this dissertation utilized a radioactivity-
based gel filtration assay (Figure 2.5). Briefly, the radioactive gel filtration assay was performed 
in triplicate 50 μL total reaction volumes.  The reaction was incubated at 37 ⁰C for 1 h, then the 
unreacted [methyl-3H] SAM and enzyme were separated from the 3H-DNA by passing through a 
Micro Bio-Spin® P-30 size exclusion column. Both negative and positive controls were also 
tested in triplicate, utilizing 10 μM S-adenosylhomocysteine as a positive control for enzyme 
inhibition.  The negative control contained the DMSO carrier without inhibitor present.  The 
column flow through was transferred to scintillation vials, and 5 mL of Ultima Gold liquid 
scintillation cocktail was added. After thorough mixing, the samples were read on a Beckman 
1500 scintillation counter, with a maximum time limit of counting fixed to 1 h.  All counts were 
reported in disintegrations per minute (dpm).  
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Figure 2.5 Schematic representation of radioactivity-based gel filtration assay.  
 
Radioactivity-based assays have advantages over other types of assays because they are 
inexpensive to use.  The radioactivity-based assays also give complete coverage of CpG sites 
allowing for global methylation analysis.  The radioactivity-based gel filtration assay was chosen 
to test the DNMT1 inhibitors because of its ease of use, and the limited amount of time needed 
to complete a test.  
 
2.5 Michaelis-Menten Kinetics 
 
The Michaelis-Menten model is one of the simplest and best-known approaches to 
enzyme kinetics (Figure 2.6).110  In the model, substrate (S) binds reversibly to an enzyme (E) for 
form an enzyme-substrate complex (ES), which then reacts irreversibly to generate a product 
(P) and regeneration of E.  
 
 
Figure 2.6. The interaction between enzyme (E) and substrate (S) and the conversion of the 
enzyme/substrate (ES) complex enzyme and product (P).  
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Leonor Michaelis and Maud Menten derived an equation that described the kinetics of 
enzyme and substrate interactions (Equation 1).  As substrate concentration is increased, a 
point is reached when all the available enzyme molecules are involved in enzyme substrate 
complexes (ES).  Plotting reaction rate (V) versus substrate concentration [s] results in a 
Michaelis-Menten plot (Figure 2.7). Enzyme saturation can be seen on the graph as a plateau 
and represents the maximum velocity (Vmax).  The point at which the concentration of substrate 
is equal to half Vmax can be used to approximate the affinity (Km) of an enzyme for that 
particular substrate. The size of the Km indicates some unique properties of the enzyme. A small 
Km indicates that the enzyme only requires a small amount of substrate to become saturated. 
This would mean that the maximum velocity would be reached at a low substrate concentration 
and that the enzyme had high affinity for the substrate.   
𝑉 =  
V𝑚𝑎𝑥 ∗ [𝑆]
K𝑚 + [𝑆]
 
Equation 1.  Michaelis-Menten equation for enzyme kinetics. 
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Figure 2.7. Michaelis-Menten plot. V is reaction rate. [S] is substrate concentration. 
 
Enzyme inhibitors interact with enzymes in several different ways to decrease the rate 
of the reaction.  For each inhibition type, a dissociation constant, Ki
’, can be calculated for the 
inhibitor that reflects the strength of interaction between the enzyme and the inhibitor.  A 
small Ki
’ value means the enzyme and inhibitor bind tightly together, while a large Ki
’
 indicates a 
weak binding between the pair. 
In competitive inhibition, the inhibitor competes with the substrate for an active site on 
the enzyme.  The rate of catalysis depends on the concentration of the inhibitor and the 
substrate.111  The conventional form of the rate equation to calculate the rate of the reaction 
with a competitive inhibitor present is shown below where [I] is the inhibitor concentration 
(Equation 2).  
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𝑉𝑜 =  
𝑉𝑚𝑎𝑥[𝑆]
𝐾𝑚 (1 +  
[𝐼]
𝐾𝑖
) + [𝑆]
 
Equation 2. Rate equation to calculate the rate of reaction when a competitive inhibitor is 
present. 
In order to normalize assays run on different days and using different isoindolinone 
samples a fractional rate Vf is reported. This fractional rate can then be compared to other rates 
found on different days.  
𝑉𝑓 =  
𝑟𝑎𝑡𝑒 (𝑤𝑖𝑡ℎ 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛)
𝑟𝑎𝑡𝑒 (𝑛𝑜 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛)
=
𝑉𝑚𝑎𝑥 [𝑆]
𝐾𝑀 (1 +  
[𝐼]
𝐾𝑖
) + [𝑆]
∗  
𝐾𝑚 + [𝑆]
𝑉𝑚𝑎𝑥 [𝑆]
 
Equation 3. Fractional rate equation. 
Equation 3 can be simplified to equation 4. 
𝑉𝑓 =  
𝐾𝑚 + [𝑆]
𝐾𝑚 (1 +  
[𝐼]
𝐾𝑖
) + [𝑆]
 
Equation 4. Simplified fractional rate equation. 
Equation 4 can be rearranged to give Ki
’
 (equation 5).  
𝐾𝑖′ =
[𝐼] 𝑉𝑓𝐾𝑚
(1 − 𝑉𝑓)( 𝐾𝑚 + [𝑆])
 
Equation 5. Equation used to calculate binding affinity of inhibitors. 
Equation 5 is an important equation, because it tells us how well our novel inhibitors bind to 
the target enzyme based on Vf and parameters set in the radioactivity-based assay.  
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Computational tools help to elucidate the basic structural requirements of inhibitors for 
activity against DNMTs.  DNMT1 is the most targeted to search for inhibitors as its high enzyme 
activity is greatest among DNMTs.112 The increase in the number of available crystallographic 
DNMTs has brought about the use of computational molecular docking and structure based 
approaches for searching for DNMT inhibitors.113-115 Computational screenings of compounds 
have helped identify many promising leads for DNMT1 inhibitors.116  
SGI-1027 is one of these promising leads that was synthesized by Datta et al.117 and 
modeled in DNMT1 by Yoo et al. (Figure 3.1).118 For the docking study, the crystal structure of 
DNMT1 with sinefungin bound (PDB id: 3SWR) was prepared to be docked by adding hydrogen 
atoms and removing water molecules within 5 Å of the crystalized sinefungin.  The chemical 
structure of SGI-1027 was built using Maestro 9.2.  The crystalized sinefungin was removed 
before the docking of the ligands began.  The results of the study show that SGI-1027 occupies 
the binding site at the same location of the known inhibitor SAH (Figure 3.1).  The same 
approach to docking studies was used for the work presented in this dissertation.  
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Figure 3.1 Docking image produced by Yoo et al. showing SGI-1027 (green) and SAH (black) 
bound to crystal structure of DNMT1.118    
 
A previous colleague of mine, Dr. Ofuka Ichire, began his graduate career, with Dr. Nigel 
Priestley’s help, by utilizing the same crystallographic structure of DNMT1 in a virtual docking 
study in order to find non-nucleoside inhibitors of DNMT1. The DNMT1 crystal structure 3SWR 
was downloaded from the Protein Data Bank and prepared using AutoDockTools.119  The 
process consisted of removing water molecules, adding hydrogens, and removing the bound 
sinefungin.  Ligands structures were obtained from the Promiliad Biopharma Incorporated 
library of compounds.  The docking calculations were performed with AutoDock Vina119 and the 
results visually displayed using Pymol (Figure 3.2).120 Briefly, calculations were performed in an 
established cube area centered on the co-crystalized sinefungin ligand.  The area covered both 
the catalytic and SAM binding sites. AutoDock Vina calculated binding energies for all ligands 
and is plotted below (Figure 3.3).  
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Figure 3.2. Docking study showing a novel inhibitor inside the active site of DNMT1. 
 
 
 
Figure 3.3 Predicted binding affinity of Promiliad Biopharma Incorporated library database. The 
blue dots represent the predicted dissociation energy for each compound tested. The red dots 
represent the top one percent of hits.  Of the 26 top hits, 17 were isoindolinone compounds.   
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Testing our group’s already existing library of compounds uncovered that a group of 
isoindolinone product analogs were predicted to bind with high affinity to DNMT1. Predicted 
binding energies for members of the library ranged from –4 to –13 kcal.mol-1. Twenty-six small 
molecules with binding energies stronger than -12.5 kcal.mol-1 comprised the top one percent 
of hits. Of these, 17 out of the 26 (65 %) were isoindolinone derivatives. The isoidolinone 
scaffold, was of interest because it is found in pharmacologically active phytotoxins (such as 
porritoxin 121 and stachybotramide 122), compound NU8231123, and the alkaloid nuevamine 
(Figure 3.4).124  
 
Figure 3.4 Isoindolinone scaffold. 
 
In an effort to study this class of compounds further, Dr. Ichire synthesized analogs of 
isoindolinones using the Ugi-IMDAF reaction (Figure 3.5).  By varying the amine and the 
isocyanide components of the reaction, a diverse library of isoindolinones were synthesized.    
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Figure 3.5. Synthetic route of Ugi-IMDAF reaction. 
 
The synthesis was divided into two separate sets of compounds: 1) isoindolinones with a 
phenol group and 2) substitution of an acetate group for the phenol 3).  Each set of compounds 
was tested in a radioactivity-based assay, with the best results shown below (Figure 3.6). The 
results of the assay show slight inhibition of DNMT1 at 100 μM.  The goal of creating this 
second group of isoindolinones was to see the importance of the phenolic OH group.  The 
results for the second set of compounds were similar to that of the first set.   
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Figure 3.6.  In vitro radioactivity assay showing top isoindolinone analogs from Dr. Ichire’s 
dissertation. The error bars are ± S.E.M.   
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The work done for this dissertation begins where Dr. Ichire left off.  The primary 
approach to produce isoindolinones is the Ugi-IMDAF reaction.  However, the one-pot Ugi-
IMDAF reactions are difficult to manage due to the number of by-products produced.  The 
IMDAF part of the reaction is reversible, so at the end of the reaction, multiple compounds are 
mixed together, making isolation of the desired product difficult and a time consuming process.  
A second issue with this reaction is a lack of commercially available isocyanides.  This limits the 
number of isoindolinone derivatives that can be produced.  
An alternative synthetic route was developed that utilized homophthalic acid as a 
starting point to successfully synthesize isoindolinones (Figure 3.7). The homophthalic acid 
route proved much easier to work with.  The addition of various primary amines was all that 
was needed to successfully synthesize a large library of diverse isoindolinones.  The downside 
to this route is that it takes multiple steps to reach the desired product.  The added steps meant 
multiple days were needed per product generated.  
 
 Figure 3.7. Homophthalic acid synthetic route.  
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 Ugi et al.  showcased a reaction scheme to produce convertible isocyanides from (β-
isocyan-ethyl)-alkyl-carbonates (Figure 3.8).125 A convertible isocyanide is an isocyanide 
functionality that can easy be converted into a series of other functional groups. This route 
proved to be the best of both previous routes, allowing us to create our own isocyanide groups 
to be used in the one pot Ugi-IMDAF reaction.  These improvements to the process of 
producing isoindolinones are discussed in the following chapters, as well as biological methods 
for analyzing the effectiveness of each new compound against DNMT1.   
 
 
 
 
Figure 3.8.  Reaction scheme for Ugi-IMDAF reaction using convertible isocyanides. 
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3.1 Ugi-IMDAF reaction to isoindolinone derivative 
 
In an effort to study the isoindolinone class of compounds, additional analogs were 
synthesized using the Ugi-IMDAF reaction. By varying the amine (R3) and the isocyanide (R2) 
components of the reaction a diverse library of isoindolinones was synthesized (Figure 3.9).  
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Figure 3.9. Structures of Ugi-IMDAF compounds made via scheme shown in Figure 3.5. 
 
3.2 Results and discussion  
 
The following tables show the Ugi-IMDAF compounds tested in the radioactivity-based 
assay. Each table shows which functional group was altered as well as the calculated binding 
affinity (Ki
’). For all the compounds tested, the results are compared to RG108 (8), since it’s a 
current successful drug candidate.  The hope is to see is a DNMT1 activity lower than 51.4% and 
a Ki
’ lower than 242 μM.   
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Compound R1 % DNMT1 Activity 
 
Ki
’  (μM) 
15 -Ph(2-Cl) 39.8 ± 1.7 
 
151 ± 11 
12 CH3 40.0 ± 1.1 
 
153 ± 7 
16 -Ph(4-OCH3) 40.3 ± 1.3 
 
155 ± 8 
13 Cyclohexane 41.7 ± 0.2 
 
164 ± 1 
23 -(+)-Ph(4-CF3) 42.7 ± 4.7 
 
171 ± 33 
8 (RG108) 
 
51.4 ± 5.7 
 
242 ± 55 
18 -Ph(4-CN) 54.4 ± 1.8 
 
273 ± 19 
22 -(-)-Ph(4-CF3) 57.4 ± 1.3 
 
309 ± 16 
19 -Ph(4-F) 64.2 ± 2.2 
 
410 ± 39 
20 -Ph(3-NO2) 64.5 ± 4.0 
 
416 ± 73 
17 -Ph(4-CF3) 68.1 ± 0.9 
 
487 ± 21 
21 -Ph(3,4-Cl2) 77.8 ± 4.7 
 
801 ± 220 
14 Ph 77.9 ± 1.7 
 
807 ± 78 
 
Table 3.1. Ugi-IMDAF products with variability in the propiolic acid position. 
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Compound R1 % DNMT1 Activity 
 
Ki
’ (μM) 
28 -Ph(2-Cl,6-Me) 39.9 ± 0.2   152 ± 1 
8 (RG108)   51.4 ± 5.7 
 
242 ± 55 
25 -Bn 54.8 ± 1.2 
 
277 ± 13 
29 -Ph(2-Me) 62.3 ± 1.8   378 ± 29 
24 -nBu 68.1 ± 0.9   487 ± 21 
26 -Ph(4-OMe) 88.5 ± 1.9   1800 ± 300 
30 -CH2CH2(3-indolyl) 90.7 ± 3.0 
 
2200 ± 800 
27 * -Ph(2,6-Me2) no significant inhibition   - 
 
Table 3.2. Ugi-IMDAF products with variability in the isocyanide position.  ‘*’ next to number 
indicates no significant inhibition. 
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Compound R1 % DNMT1 Activity 
 
Ki
’ (μM) 
34 -CH2Ph(4-Ph) 31.3 ± 0.6 
 
104 ± 3 
8 (RG108) 
 
51.4 ± 5.7 
 
242 ± 55 
38 -(5-quinolonyl) 53.6 ± 0.9 
 
264 ± 10 
37 -CH2CH2-(3-indolyl) 58.0 ± 1.2 
 
315 ± 15 
36 -CH2Ph(4-Me) 62.3 ± 2.6 
 
378 ± 42 
32 -CH2Ph(4-
tBu) 68.1 ± 0.9 
 
490 ± 20 
35 -CH2Ph(4-
iPr) 68.9 ± 1.7 
 
508 ± 41 
31 -CHPh2 87.2 ± 1.2 
 
1600 ± 200 
33 -Bn 88.4 ± 2.7 
 
1800 ± 500 
 
Table 3.3. Ugi-IMDAF products with variability in the amine position. 
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Compound R1 % DNMT1 Activity 
 
Ki
’ (μM) 
8 (RG108) 
 
51.4 ± 5.7 
 
242 ± 55 
45 -OiPr 59.3 ± 1.9 
 
333 ± 26 
47 -H 66.8 ± 5.6 
 
461 ± 117 
39 -OH 68.9 ± 1.7 
 
507 ± 41 
46 -OSO2Me 70.6 ± 3.0 
 
550 ± 78 
40 -OMe 83.6 ± 5.1 
 
1200 ± 450 
44 -OCamphSulf 88.8 ± .07 
 
1800 ± 130 
41 * -OnPr no significant inhibition 
 
- 
42 * -OnC6H11 no significant inhibition 
 
- 
43 * -OCH2CH2CH2OH no significant inhibition 
 
- 
 
Table 3.4. Ugi-IMDAF products with variability in the hydroxyl group position. ‘*’ next to 
number indicates no significant inhibition. 
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Varieties of isoindolinone compounds have been tested in this study. Each set of 
compounds were carefully designed as an SAR approach to arrive at the best possible 
isoindolinone.  The goal of this study is to find a novel inhibitor that creates a lower DNMT1 
activity and Ki
’ than RG108 (8). Each of the first series of products contains the amines n-
butylamine and tert-butylamineuamine and has a phenolic OH group present while having 
variability in the propiolic acid position (Table 3.1). 
The results show several compounds that exhibit more potent DNMT1 inhibition as 
compared to RG108.  Compound 12 has a methyl group at the R1 site.  This compound has a 
DNMT1 activity of 40.0 ± 1.1. This is an 11.4 % decrease from RG108.  The calculated Ki
’ value 
for compound 12 is 153 ± 7 μM, which is 89 μM lower than RG108.  Next, we see compound 13 
with a cyclohexane present at the R1 site. This compound has a DNMT1 activity of 41.7 ± 0.2. 
Compound 13 showed a 9.7 % decrease from RG108. The calculated Ki
’ value for compound 13 
is 164 ± 1μM, which is 78 μM lower than RG108.  
Compound 15 contains a 2-chlorobenzene group at the R1 site. Compound 15 has a 
DNMT1 activity of 39.8 ± 1.7. When comparing this to RG108, we a see an 11.6 % decrease in 
activity.  The calculated Ki
’ value for 15 is 151 ± 11, which is 91 μM less than RG108. Compound 
16 has a –Ph(4-OCH3) group at the R1 site. Compound 16 has a DNMT1 activity of 40.3 ± 1.3. 
When comparing this to RG108, we a see an 11.1 % decrease in activity. .  The calculated Ki 
value for 16 is 155 ± 8, which is 87 μM less than RG108.  The final compound that showed 
improvement on RG108 in this series is number 23. Compound 23 has a Ph(4-CF3) group in the 
R1 site and a DNMT1 activity of 42.7 ± 4.7. This value is a 8.7 % decrease when compared to the 
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activity of RG108.  The calculated Ki
’ for compound 23 is 171 ± 33, which is 71 μM lower than 
RG108.  
The next series of compounds has variability in the isocyanide position (Table 3.2).  As 
mentioned above, there is a limited number of commercially available isocyanides, making this 
series of compounds smaller in number than most.  Each of the compounds made in the series 
contains the amine tbutylamine, has a 4-CF3 phenyl group, and has a phenolic OH group 
present.  Of the seven compounds tested in this series one compound, 28, showed an 
improvement when compared to RG108.  Compound 28 has a –Ph(2-Cl,6-Me) group present.  
This compound gave a DNMT1 activity of 39.9 ± 0.2, which is an 11.5 % decrease from RG108.  
The calculated Ki
’ value for compound 28 is 152 ± 1 μM, which is 90 μM lower than RG108.  This 
series of compounds tells us there is a need for some sort of electron donating group in the R1 
position. 
 The next series of compounds are Ugi-IMDAF reaction products with variability in the 
amine position (Table 3.3). Each of the compounds made in the series contains the n-butyl 
amine, has a 4-CF3 phenyl group, and has a phenolic OH group present.  Of the eight 
compounds tested, only compound 34 showed an improvement when compared to RG108. 
Compound 34 has a –CH2Ph(4-Ph) group at the R1 site. The DNMT1 activity for compound 34 
was 31.3 ± 0.6.  This value is 20.1 % lower in activity than RG108.  The calculated Ki
’ value for 
this compound is 104 ± 3 μM, which is 138 μM less than RG108.   
In Table 3.4, we show the results for a series of Ugi-IMDAF products generated with 
variability in the hydroxyl group position. Each of the compounds made in the series contains 
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the amines n-butyl isocyanide, 4-isopropylbenzyl amine, has a 4-CF3 phenyl group. Of the nine 
compounds tested, none of them showed improvement on the DNMT1 activity or the 
calculated binding affinity when compared to RG108.  These results tell us that leaving a 
hydroxyl group on the ring would give us the desired lower DNMT1 activity.  
Of all the Ugi-IMDAF products tested so far compound 34 has the best improvement in 
DNMT1 inhibition when compared to RG108.  Next, we decided to create a new series of 
compounds that would get around the issues presented in the Ugi-IMDAF synthetic route. The 
route created utilizes homophthalic acid as a starting material and creates the desired 
isoindolinone structures.  The results for these series of compounds are seen in tables 4.1 – 4.3. 
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 HOMOPHTHALIC ACID SYNTHETIC ROUTE TO PRODUCE Chapter 4
ISOINDOLINONES 
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4.1 Introduction 
 
The one-pot Ugi-IMDAF reaction generated the desired isoindolinone structures with 
overall yields between 54% and 89%.  The use of the reaction in a true combinatorial sense is 
limited as each reaction required individual optimization. Difficulties were observed with the 
initial Ugi condensation and particularly with the reversibility of the Diels-Alder reaction.  This, 
along with a limited number of commercially available isocyanides makes that synthetic route 
not as useful as at first. Here we discuss an approach to synthesize novel isoindolinones using a 
multi-step synthesis scheme (Figure 4.1). Briefly, homophthalic acid, 48, is dissolved in 
methanol with 5% v/v H2SO4 to create the Fischer esterification product 49.  49 undergoes a 
benzylic bromination reaction to produce compound 50, which then undergoes a SN2 reaction 
followed by an intramolecular cyclization by the addition of a primary amine, to produce 
compounds 51-55. The methyl esters in compounds 51-55 go through hydrolysis to produce the 
carboxylic acids, compounds 68-71. The carboxylic acids are then activated and undergo a 
reductive amination reaction to produce compounds 56-67. The structures of products 
generated via this route are show below (Figure 4.2).  
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Figure 4.1. Reaction scheme for homophthalic acid multi-step synthesis.  
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Figure 4.2. Structures of isoindolinone compounds made via scheme shown in Figure 4.1. 
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4.2 Results and discussion 
 
 
 
 
 
Compound 
R1 R2 
% DNMT1 
Activity  
Ki
’ (μM) 
8 (RG108) 
  
51.4 ± 5.7 
 
242 ± 55 
51 * benzyl -OMe 
no significant 
inhibition  
- 
52 * 
-CH2CH2-(3-
indoyl) 
-OMe 
no significant 
inhibition  
- 
53 * -NHPH -OMe 
no significant 
inhibition  
- 
54 * -CH2Ph(4-
tBu) -OMe 
no significant 
inhibition  
- 
55 * -NHPh(4-tBu) -OMe 
no significant 
inhibition 
  - 
 
Table 4.1. Homophthalic acid synthetic route products varying R1 while keeping R2 a methyl 
ester. ‘*’ next to number indicates no significant inhibition. 
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Compound R1 R2 % DNMT1 Activity 
 
Ki
’ (μM) 
8 (RG108) 
  
51.4 ± 5.7 
 
242 ± 55 
67 -CH2Ph(4-iPr) -NHCH2Ph(4-
iPh) 58.0 ± 0.59 
 
316 ± 8 
66 -CH2CH2-(3-indoyl) -NHCH2CH2CH3 72.9 ± 4.9 
 
614 ± 151 
57 -CH2Ph -NHCH2CH2-(3-indoyl) 76.3 ± 4.3 
 
736 ± 174 
56 * -CH2CH2CH3 -NHCH2CH2CH3 
no significant 
inhibition  
- 
58 * -CH2Ph -NHCH2Ph(3-F) 
no significant 
inhibition  
- 
59 * -CH2Ph(3-Me) -NHCH(CH3)2 
no significant 
inhibition  
- 
60 * Cyclohexane -NHCH(CH3)2 
no significant 
inhibition  
- 
61 * Cyclohexane -NHCH2CH2CH3 
no significant 
inhibition  
- 
62 * Cyclohexane -NHCH2CH2morpholine 
no significant 
inhibition  
- 
63 * Cyclohexane -NHcyclohexane 
no significant 
inhibition  
- 
64 * Cyclohexane -NHCH2CH2-(3-indoyl) 
no significant 
inhibition  
- 
65 * Cyclohexane -NHCH2Ph 
no significant 
inhibition  
- 
 
Table 4.2. Homophthalic acid synthetic route products varying R1 and R2. ‘*’ next to number 
indicates no significant inhibition. 
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Compound R1 R2 
% DNMT1 
Activity  
Ki
’  (μM) 
70 -CH2Ph -OH 8.91 ± 0.16 
 
22 ± 0.45 
68 -CH2CH2-(3-indoyl) -OH 10.2 ± 1.7 
 
26 ± 5 
73 -CH2Ph(3-NO2) -OH 24.3 ± 3.4 
 
74 ± 13 
72 -CH2Ph(3-F) -OH 28.3 ± 0.65 
 
90 ± 3 
8 (RG108) 
  
51.4 ± 5.7 
 
242 ± 55 
69 * -CH2CH2CH3 -OH 
no significant 
inhibition  
- 
71 * -CH2Ph(4-
tBu) -OH 
no significant 
inhibition  
- 
 
Table 4.3. Homophthalic acid synthetic route products varying R1 and having a carboxylic acid 
functionality at R2 site. ‘*’ next to number indicates no significant inhibition. 
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Figure 4.3. Homophthalic acid isoindolinone scaffold. 
Table 4.1 shows products of the homophthalic acid route with variability in the R1 
position but keeping the R2 site a methoxy. These results suggested to us that the methoxy 
group in the R2 site is not needed and should be changed.  
Compound R1 R2 % DNMT1 Activity 
 
Ki’ (μM) 
8 (RG108) 
  
51.4 ± 5.7 
 
242 ± 55 
67 -CH2Ph(4-iPr) -NHCH2Ph(4-iPh) 58.0 ± 0.59 
 
316 ± 8 
66 -CH2CH2-(3-indoyl) -NHCH2CH2CH3 72.9 ± 4.9 
 
614 ± 151 
57 -CH2Ph -NHCH2CH2-(3-indoyl) 76.3 ± 4.3 
 
736 ± 174 
56 * -CH2CH2CH3 -NHCH2CH2CH3 
no significant 
inhibition  
- 
58 * -CH2Ph -NHCH2Ph(3-F) 
no significant 
inhibition  
- 
59 * -CH2Ph(3-Me) -NHCH(CH3)2 
no significant 
inhibition  
- 
60 * Cyclohexane -NHCH(CH3)2 
no significant 
inhibition  
- 
61 * Cyclohexane -NHCH2CH2CH3 
no significant 
inhibition  
- 
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62 * Cyclohexane -NHCH2CH2morpholine 
no significant 
inhibition  
- 
63 * Cyclohexane -NHcyclohexane 
no significant 
inhibition  
- 
64 * Cyclohexane -NHCH2CH2-(3-indoyl) 
no significant 
inhibition  
- 
65 * Cyclohexane -NHCH2Ph 
no significant 
inhibition  
- 
 
Table 4.2 shows the result of changing the R2 site. 
Compounds 56 – 67 were synthesized in order to test the effects of altering both the R1 
and R2 site.  Of the twelve compounds tested, only three of them, compounds 57, 66, and 67 
showed statistically significant inhibition.  Compound 57 has a –CH2Ph on the R1 site and a -
NHCH2CH2-(3-indoyl) in the R2 site. This compound resulted in a DNMT1 activity of 76.3 ± 4.3, 
which is 24.9 % higher than RG108. The calculated Ki
’ value is 494 μM larger than RG108, 
indicating this combination of variables is not the way to go. Compound 66 has a DNMT1 
activity of 72.9 ± 4.9, which is 21.5 % higher than RG108 and a calculated Ki
’ value of 614 ± 151 
μM, which is 372 μM higher than RG108.  Compound 67 gave a DNMT1 activity of 58.0 ± 0.59, 
which is 6.6 % higher than RG108.  The calculated Ki
’ value for compound 67 is 316 ± 8 μM, 
which is 74 μM higher than RG108. It is clear that this series of compounds did not surpass the 
current RG1008 standard.  
The results for the isoindolinones that vary in the R1 site, but have a hydroxyl group at 
the R2 site show that of the six compounds tested, four of them show significant results. (Table 
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4.3) Compound 68 has a DNMT1 activity of 10.2 ± 1.7. This value is 41.2 % lower than RG108.  
The calculated Ki
’ value is 26 ± 5 μM, which is 216 μM lower than RG108.  The second 
compound in the series with significant results is number 70.  Compound 70 has a DNMT1 
activity of 8.91 ± 0.16. This value is 42.5 % lower than RG108.  The calculated Ki
’
 value for 
compound 70 is 22 ± 0.45 μM, which is 220 μM lower than RG108. Compound 72 has a DNMT1 
activity of 28.3 ± 0.65. This value is 23.1 % lower than RG108.  The calculated Ki
’ value is 90 ± 3, 
which is 152 μM lower than RG108.  Compound 73 has a DNMT1 activity of 24.3 ± 3.4. This 
value is 27.1 % lower than RG108.  The calculated Ki
’ value is 74 ± 13, which is 168 μM lower 
than RG108. The results for compound 68, 70, 72, and 73 were tested multiple times to insure 
the results were not a fluke. Each time the data came to the same conclusion.  It is clear from 
the results that the carboxylic acid functionality at the R2 site greatly helps the inhibition 
property.  
The homophthalic acid synthetic route produced the desired isoindolinone compounds 
in good yields. The synthetic route required no isocyanides, providing a way to get around the 
issue with the Ugi-IMDAF reaction. The process to isolate and purify the products was much 
easier than the Ugi-IMDAF reactions.  The main issue with the homophthalic acid reaction is 
that it is a multiple step process as there are no reversible steps to overcome.  The need to 
purify after each step adds time to the isoindolinone creation process. Overall, though, this is a 
great synthetic route to create isoindolinone DNMT1 inhibitors.  
  
58 
 
 CONVERTIBLE ISOCYANIDES SYNTHETIC ROUTE TO PRODUCE Chapter 5
ISOINDOLINONES 
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5.1 Introduction 
 
After showing the capability of the homophthalic acid synthetic route to make 
isoindolinones (Figure 4.1), we wanted to return to the Ugi-IMDAF reaction. The one-pot Ugi-
IMDAF reactions generated the desired isoindolinone structures with overall yields between 54 
% and 89%.   The use of the reaction in a true combinatorial sense is limited, as each reaction 
required individual optimization. Difficulties were observed with the initial Ugi condensation 
and particularly with the reversibility of the Diels-Alder reaction.  That, along with a limited 
number of isocyanides makes that synthetic route not desirable.   Lindhorst et al., however, 
showed the synthesis of a new class of convertible isocyanides and use of them in the Ugi-
IMDAF reaction (Figure 5.1).125 A convertible isocyanide can easily be changed into a carboxylic 
acids and other functionalities.  The convertible isocyanide is very simple to make with 4,4-
dimethyl-2-oxazoline, 74, being deprotonated with n-BuLi and the resulting lithium alcoholate 
being captured with an alkyl chloroformate, 75.  This product, 76, can then be used in the one 
pot Ugi-IMDAF reaction. This process allows us to use the one pot Ugi-IMDAF reaction, while 
avoiding the issues of limited commercially available isocyanides. The structures of the products 
generated are shown below (Figure 5.2).  
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 Figure 5.1. Reaction scheme for Ugi-IMDAF reaction using convertible isocyanides.  
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Figure 5.2. Structures of Ugi-IMDAF compounds made via scheme shown in  
 Figure 5.1. Reaction scheme for Ugi-IMDAF reaction using convertible isocyanides.  
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5.2 Results and discussion  
 
 
 
 
Compound R1 R2 
% DNMT1 
Activity  
Ki
’  (μM) 
78 -CH2Ph(4-
tBu) -OH 7.31 ± 0.98 
 
18 ± 3 
8 (RG108) 
  
51.4 ± 5.7 
 
242 ± 55 
77 -CH2Ph(4-
tBu) 
 
55.7 ± 4.3 
 
287 ± 50 
79 -CH2Ph(4-
tBu) 
-NHCH2CH2-(3-
indolyl) 
90.7 ± 3.0 
 
2300 ± 800 
80 * 
-CH2Ph(3,4-
dichloro) 
 
no significant 
inhibition  
- 
81 * 
-CH2PH(4-
methoxy) 
 
no significant 
inhibition  
- 
 
Table 5.1. Convertible isocyanide synthetic route products varying R1 and R2 site. ‘*’ next to 
number indicates no significant inhibition.   
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Figure 5.3. Convertible isocyanide isoindolinone scaffold. 
 
Synthesizing our own convertible isocyanides allowed us to create a wider range of Ugi-
IMDAF products (Table 5.1). Of the five compounds tested in the series, four of them did not 
have significant inhibition. Compound 77 has a -CH2Ph(4-
tBu) in the R1 site and one of our 
synthesized isocyanides at the R2 site.  The DNMT1 activity for this compound is 55.7 ± 4.3.  This 
value is 4.3 % higher than RG108.  The calculated Ki
’ value for this compound is 287 ± 50 μM, 
which is 45 μM higher than RG108.  Compound 78 has a -CH2Ph(4-
tBu) in the R1 site and a 
hydroxyl group at the R2 site. As we saw with the results in Table 4.3, when a carboxylic acid 
moiety is present on the compound the inhibition property of the compound increases. The 
DNMT1 activity for compound 78 is 7.31 ± 0.98. This value is 44.1 % lower than RG108.  The 
calculated Ki
’
 value for the compound is 18 ± 3 μM, which is 224 μM lower than RG108.  
Compound 79 has a -CH2Ph(4-
tBu) on the R1 site and one of our synthesized isocyanides at the 
R2 site, but failed to perform better than RG108. Compound 79 has a DNMT 1 activity of 90.7 ± 
3.0. This value is 39.3 % higher than RG108.  The calculated Ki
’
 value for the compound is 2058 
μM higher than RG108.     
It is clear from the results that a carboxylic acid is needed in order to improve the 
inhibition of the DNMT1 inhibitors.  This was observation was also seen in the homophthalic 
acid compounds 68, 70, 72 and 73. 
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 FUTURE DIRECTIONS Chapter 6
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6.1 Synthesis 
 
It is clear from looking at all of the results that a carboxylic acid functionality is needed to 
enhance the inhibition properties of the novel inhibitors. We see the increased inhibition in the 
Ugi-IMDAF products as well as the homophthalic acid products as long as the carboxylic acid 
was present.  Looking at the docking image for compound 68, we can see interactions with the 
nearby conserved amino acids that might help explain the strength of the inhibition (Figure 
6.1). The strength of inhibition could be in part due to the interactions that the carboxylic acid 
has in compound 68 with ALA 1579 in the active site of DNMT1. Or perhaps, compound 68 
creates a strong π-π interaction with PRO 1225.     
 
Figure 6.1. Docking image for compound 68 with active site of DNMT1. 
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The docking image for compound 70 shows that the isoindolinone ring overlaps well with 
the PRO 1225 (Figure 6.2). The carboxylic acid functionality also displays interactions with ASN 
1578.  Analyzing the docking image of compound 75 shows similar interactions with how the 
Phenyl(4-CF3) ring overlaps well with PRO 1225 (Figure 6.3). The PRO residue also overlaps well 
with the phenyl ring in the tbutyl amine. The carboxylic acid functionality shows an interaction 
with TRP 1170 and the OH shows interactions with ASN 1578. These overlaps create strong 
interactions that hold the inhibitor in place, thus blocking access to the active site.   
 
 
 
Figure 6.2. Docking image for compound 70 with active site of DNMT1. 
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Figure 6.3. Docking image for compound 75 with active site of DNMT1. 
 
The great thing about this research project is that the molecules made are modular and 
can be altered with ease. One direction this project can go is to create a series of compounds 
using the homophthalic acid synthetic route with functional groups on the ring (Figure 6.4). The 
series begins by synthesizing 5-nitrohomophthalic acid 82, which can be obtained by selective 
nitration of homophthalic acid 48.126 Compound 83 is achieved my reducing the nitro group in 
82 to an amine by catalytic hydrogenation on 10% Pd/C.127  The amine is then protected with 
phthalic anhydride to make compound 84.128 Compound 85, A, and B are prepared like their 
counterparts (Figure 4.1). The amine protecting group is removed to create compound in series 
C.   Diazotation using sodium nitrate will give the diazonium salt series D. Series D can be 
converted to series E by reacting with cuprous halides or by hydrolysis by sulfuring acid. C can 
68 
 
be treated with acyl chlorides in a KOH solution to yield the compounds in series F.  Series C can 
easily be converted to the series H by simple esterification techniques. These new series of 
compounds will allow us to evaluate the importance of different types of functional groups on 
the ring as well on the R4 position.  
6.2 Competition studies  
 
This dissertation research relied upon computational calculations to extrapolate Ki
’ values 
based on one time point and a single concentration.  This process was reliable and resulted in 
the identification of new lead compounds. To take this research a step further, the current lead 
compounds could be examined in a competition study as outlined by Gros et al.107 In this study, 
the leads will be tested in a SAM-competition assay and DNA-competition assay.  
In the SAM- competition assay, the SAM concentration will be varied, while the DNA 
concentration will be fixed. For each SAM concentration, the lead compounds concentrations 
will be adjusted between IC10 and its IC80.  In the DNA-competition assay, the DNA 
concentration will be varied, while the SAM concentration will be fixed. For each DNA 
concentration, the lead compounds concentration will be adjusted between IC10 and its IC80.   
For each substrate concentrations, the IC50 of the tested compound will be calculated by 
non-linear regression fitting with sigmoidal dose response.  For each compound concentration, 
Km and Vm of each substrate will be approximated by non-linear fitting of the data with the 
Michaelis-Menten equation. This study will allow us to confirm if our lead compounds act as 
competitive inhibitor.  
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Figure 6.4. Future directions for project.  
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 EXPERIMENTAL SECTION Chapter 7
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Experimental Section General Procedures.  Solvents were obtained from Fisher Scientific. All 
other chemicals, unless noted otherwise, were obtained from the Aldrich Chemical Co. 
(Milwaukee, WI). The solvents MeOH (over Mg(OMe)2) and THF (over Na/K-benzophenone) 
were dried and distilled prior to use. Solutions were concentrated by evaporation in vacuo. All 
synthesis procedures, unless noted otherwise, were carried out under a slight positive pressure 
of argon gas at ambient temperature (21-25 °C). Column chromatography was performed using 
Merck Silica Gel 60. NMR spectra were acquired at 400 MHz (1H) and 100 MHz (13C), were 
referenced to the residual solvent, and are reported as follows: chemical shift (δ/ppm), splitting 
pattern, coupling constant (J/Hz), and intensity.  
 
Radioactivity-based assay procedure 
Reagents. A 10X buffer solution (BP1) was prepared (pH = 7.8 ,50.0 mM Tris-HCl, 1.0 mM EDTA, 
5% v/v glycerol) and used in the reaction buffer (1X BP1, 0.1 mg.mL-1 bovine serum albumin 
(BSA) with 3.0 mM dithiothreitol (DTT)).   
Radioactivity-based assay.  The radioactivity-based gel filtration assay was performed in 
triplicate (50 μL total reaction volumes), containing the test compound (250 μM, in 5% v/v 
DMSO), [methyl-3H] SAM (0.372 μM in H2O, PerkinElmer, 15 Ci.mmol
-1), poly(deoxyinosinic-
deoxycytidylic) acid sodium salt (1.8 μg, Sigma Aldrich), reaction buffer and DNMT1 (25.0 ng, 
BPS Bioscience).  The reaction was incubated at 37 ⁰C for 1 h, then the tritium labeled DNA 
separated by passing through a Micro Bio-Spin® P-30 size exclusion column (Bio-Rad).  Both 
negative (DMSO carrier with no inhibitor present) and positive controls (S-
adenosylhomocysteine, 10 μM, Sigma Aldrich) were also tested in triplicate.  The column eluate 
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was transferred to scintillation vials with Ultima Gold liquid scintillation cocktail (5 mL, 
PerkinElmer).  After thorough mixing, the samples were read on a Beckman 1500 scintillation 
counter, with a maximum time limit of counting fixed to 1 h.  All counts were reported in 
disintegrations per minute (dpm). 
 
 
49: Methyl 2-(2-methoxy-2-oxoethyl)benzoate: A solution of 48 (10.0 g, 55.5 mmol) in 
MeOH (100 mL) was heated to 30 ⁰C for 10 minutes. H2S04 (5.0 ml, 5% v/v) was added 
and the reaction heated to reflux for 2 hours. The progress of the reaction was followed 
by TLC (EtOAc-hexanes , 1:1).  When 48 had been consumed the reaction was allowed 
to cooled to room temperature and neutralized to pH 7 with aq. sat. NaHCO3 solution (5 
mL) and extracted with EtOAc (3 × 5 mL).  The organic extracts were combined, dried 
over anhyd. Na2SO4, and concentrated by evaporation in vacuo to afford a yellow oil 
(9.57g, 83%).  Compound 49 was used in the subsequent step without further 
purification.  1H NMR (400 MHz, CDCl3) δ ppm 7.99 (d, J =7.8 Hz, 1H), 7.43 (t, J = 7.5 Hz, 
1H), 7.31 (t, J = 7.5 Hz, 1H) 7.22 (d, J = 7.5 Hz, 1H), 3.98 (s, 2H), 3.82 (s, 3H), and 3.65 (s, 
3H).  13C NMR (100 MHz, CDCl3) δ ppm 171.48, 167.03, 135.67, 131.94, 130.60, 129.24, 
127.03, 51.53, 51.43, and 40.04.  This known compound was synthesized following the 
procedure outlined by Wang et al.129 
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50: Methyl 2-(1-bromo-2-methoxy-2-oxoethyl)benzoate: A solution of 49 (9.57 g, 46.0 
mmol) in CCl4 (70 mL) was heated at reflux for 5 min.  N-Bromosuccinimide (16.50 g, 
92.70 mmol) was added followed by AIBN (0.77 g, 4.7 mmol) and two drops of aq. HBr 
(45 % w/v), the progress of the reaction followed by TLC (EtOAc-hexanes, 1:1). When 
49 had been consumed the reaction was allowed to cool to rt, filtered and the filtrate 
concentrated by evaporation in vacuo to give an oil. Compound 50 was obtained by 
chromatography on silica gel, eluting with EtOAc-hexanes (7-25% gradient) as a yellow 
oil (8.10 g, 62%). 1H NMR (400 MHz, CDCl3) δ ppm 7.97 (d, J = 6.5 Hz, 1H), 7.88 (d, J = 
6.9 Hz, 1H), 7.58 (t, J = 7.6 Hz, 1H), 7.41, (t, J = 7.7 Hz, 1H), 6.59 (s, 1H), 3.92 (s, 3 H), 
and 3.79 (s, 3H). 13C NMR (100 MHz, CDCl3) δ ppm 169.04, 166.90, 137.04, 132.75, 
131.54, 130.64, 128.72, 128.18, 53.27, 52.36 and 43.97.  This known compound was 
synthesized following the procedure outlined by Kim et al.130  
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51: Methyl 2-benzyl-3-oxoisoindoline-1-carboxylate: A solution of methyl 2-(1-bromo-2-
methoxy-2-oxoethyl)benzoate (308 mg, 1.07 mmol) in MeOH (20 mL) was stirred at 
room temperature for 5 minutes. Dropwise addition of 30% benzylamine (588µL, 5.38 
mmol) in MeOH was added over 30 minutes and the progress of the reaction followed 
by TLC (EtOAc-hexanes, 1:1).  When the starting material had been consumed the 
reaction was quenched with 2M HCl (10 mL) and extracted with EtOAc (3 × 15 mL).  The 
organic extracts were combined, dried over anhyd. Na2SO4, and concentrated by 
evaporation in vacuo to afford a brown oil.  51 was obtained by chromatography on 
silica gel, eluting with EtOAc-hexanes-triethylamine (75:25:1) as a white solid (117.1 
mg,  33.3%). 1H NMR (400 MHz, CDCl3) δ ppm 7.90 - 7.96 (m, 1H), 7.53 - 7.61 (m, 3H), 
7.25 - 7.40 (m, 5H), 5.50 (d, J = 15.1 Hz, 1H), 4.97 (s, 1H), 4.32 (d, J = 15.1 Hz, 1H), and 
3.79 (s, 3H). 13C NMR (100 MHz, CDCl3) δ ppm 168.7, 139.2, 136.3, 131.9, 129.3, 128.8, 
128.5, 127.8, 124.1, 122.8, 77.3, 77.2, 76.7, 61.2, 52.9, and 45.1.  HRMS (ESI-TOF) m/z 
calcd. for C17H16NO3: 335.1390; found 335.1389 ([M + H]
+, ∆ ppm 0.23). 
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52: Methyl 2-(2-(1H-indol-2-yl)ethyl)-3-oxoisoindoline-1-carboxylate: A solution of methyl 
2-(1-bromo-2-methoxy-2-oxoethyl)benzoate (2.87 g, 10.0  mmol) in MeOH (200 mL) 
was stirred at room temperature for 5 minutes. Dropwise addition of 30% tryptamine 
(6.73 g, 50.0 mmol) in MeOH was added over 30 minutes and the progress of the 
reaction followed by TLC (EtOAc-hexanes, 1:1).  When the starting material had been 
consumed the reaction was quenched with 2M HCl (10 mL) and extracted with 
methylene chloride (3 × 60 mL).  The organic extracts were combined, dried over 
anhyd. Na2SO4, and concentrated by evaporation in vacuo to afford orange oil.  52 was 
obtained by chromatography on silica gel, eluting with EtOAc-hexanes-triethylamine 
(25:75:1) as a orange solid (2.87 g, 86%). 1H NMR (400 MHz, CDCl3) δ ppm 8.57 (bs, 1H), 
7.84 - 7.88 (m, 1H), 7.63 (d, J = 8.0 Hz, 1H), 7.63 (d, J = 8.0 Hz, 1H), 7.46 - 7.54 (m, 3H), 
7.36 (td, J = 0.9, 8.03 Hz, 1H), 7.18 (dt, J = 1.1, 7.59 Hz, 1H), 7.10 (ddd, J = 1.1, 7.0, 7.9 
Hz, 1H), 7.01 (d, J = 2.5 Hz, 1H), 5.02 (s, 1H), 4.49 (s, 1H), 3.70 (s, 3H), 3.58 - 3.68 (m, 
1H), and 3.10 - 3.22 (m, 2H) 13C NMR (100 MHz, CDCl3) δ ppm 168.8, 168.8, 139.4, 
136.5, 132.0, 131.9, 129.3, 127.2, 123.8, 122.8, 122.1, 122.1, 119.3, 118.6, 112.5, 
111.4, 62.5, 60.4, 52.9, 41.9, 24.2, 21.1, and 14.2.  HRMS (ESI-TOF) m/z calcd. for 
C20H19N2O3: 282.1125; found 282.1124 ([M + H]
+, ∆ ppm 0.27). 
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53:  Methyl 3-oxo-2-(phenylamino)isoindoline-1-carboxylate: A solution of phenyl 
hydrazine (0.13 mL, 1.31 mmol) in DMF (0.30 mL) was stirred at room temperature for 
5 minutes. Trimethylamine (0.24 mL, 1.74 mmol) followed by a solution of methyl 2-(1-
bromo-2-methoxy-2-oxoethyl)benzoate (0.265 g, 0.92 mmol) in DMF (0.14 mL) was 
added and the progress of the reaction followed by TLC (EtOAc-hexanes, 1:1).  When 
the starting material had been consumed, the reaction was quenched with EtOAc, and 
washed with aq. NaHCO3. The organic extracts were combined, dried over anhyd. 
Na2SO4, and concentrated by evaporation in vacuo to afford a brown oil.  53 was 
obtained by chromatography on silica gel, eluting with EtOAc-hexanes (10-35% 
gradient) as an orange solid (91.8 mg,  35.2%). 1H NMR (400 MHz, (CD3)2SO) δ ppm 7.96 
(d, J = 7.5 Hz, 1H), 7.66 (d, J = 4.0 Hz, 2H), 7.55 - 7.62 (m, 1H), 7.21 - 7.27 (m, 2H), 6.90 - 
6.96 (t, J = 7.4 Hz, 1H), 6.75 - 6.80 (m, 2H), 6.40 (s, 1H), 5.45 (s, 1H), and 3.84 (s, 3H). 13C 
NMR (100 MHz, (CD3)2SO) δ 168.5, 166.3, 147.3, 138.3, 132.9, 130.1, 129.5, 128.8, 
123.6, 123.3, 119.3, 112.4, 63.4, and 53.0. 
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54: Methyl 2-(4-(tert-butyl)benzyl)-3-oxoisoindoline-1-carboxylate: A solution of 4-tert-
butylbenzyleamine (1.02 mL, 5.80 mmol) in THF (2.62 mL) was stirred at room 
temperature for 5 minutes. Triethylamine (0.88 ml, 6.29 mmol) was added dropwise 
and the reaction solution was brought to 0 ⁰C. Methyl 2-(1-bromo-2-methoxy-2-
oxoethyl)benzoate (1.51 g, 5.25 mmol) was added and the progress of the reaction 
followed by TLC (EtOAc-hexanes, 1:1).  When the starting material had been 
consumed, the reaction was quenched with 2M HCl (30 mL) and extracted with EtOAc 
(3 × 60 mL).  The organic extracts were combined, dried over anhyd. Na2SO4, and 
concentrated by evaporation in vacuo to afford a yellow oil.  54 was obtained by 
chromatography on silica gel, eluting with EtOAc-hexanes-triethylamine (25:75:1) as a 
clear oil (1.40 g, 79.8%).1H NMR (400 MHz, CDCl3) δ ppm 7.87 - 7.94 (m, 1H), 7.48 - 7.57 
(m, 3H), 7.34 (d, J = 8.0 Hz, 2H), 7.20 (d, J = 8.2 Hz, 2H), 5.44 (d, J = 14.8 Hz, 1H), 4.96 (s, 
1H), 4.26 (d, J = 14.8 Hz, 1H), 3.77 (s, 3H), and 1.27 - 1.32 (m, 9H). 13C NMR (100 MHz, 
CDCl3) δ ppm 168.7, 168.3, 150.8, 139.2, 133.2, 131.9, 131.8, 129.2, 128.9, 128.2, 
127.7, 125.7, 125.6, 125.2, 124.1, 122.8, 61.2, 52.9, 44.7, 34.5, and 31.3. 
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55: Methyl 2-((4-(tert-butyl)phenyl)amino)-3-oxoisoindoline-1-carboxylate: A solution of 
4-tert-butylphenylhydrazine monohydrochloride (0.40 g, 2.0 mmol) in THF (1.0 mL) was 
stirred at room temperature for 5 minutes. Triethylamine (1.23 mL, 8.8 mmol) and 
DMF (0.2 mL) was added and the reaction solution brought to 0 ⁰C. A solution of 
methyl 2-(1-bromo-2-methoxy-2-oxoethyl)benzoate (0.50 g, 1.7 mmol) in DMF (0.50 
mL) was added and the reaction progress followed by TLC (EtOAc-hexanes, 1:1).  When 
the starting material had been consumed, the reaction was quenched with EtOAc, and 
washed with aq. NaHCO3. The organic extracts were combined, dried over anhyd. 
Na2SO4, and concentrated by evaporation in vacuo to afford a brown oil.  55 was 
obtained by chromatography on silica gel, eluting with EtOAc-hexanes (5-25% gradient) 
as an orange solid (91.8 mg, 14.2%).1H NMR (400 MHz, CDCl3) δ 8.08 (dd, J = 1.3 Hz, 7.8 
Hz, 1H), 7.52 (dt, J = 1.5 Hz, 7.53 Hz, 1H), 7.45 (m, 2H), 7.29 (m, 1H), 7.24 (m, 2H), 7.00 
(m, 2H), 5.45 (s, 1H), 3.80 (s, 3H), and 1.24 (s, 9H).  13C NMR (100 MHz, CDCl3) δ 169.2, 
164.6, 146.4, 146.0, 133.9, 133.2, 129.0, 127.5, 127.4, 126.3, 126.2, 116.8, 66.4, 53.1, 
34.1, and 31.3.  HRMS (ESI-TOF) m/z calcd. for C20H23N2O3: 339.1703; found 339.1711 
([M + H]+, ∆ ppm 2.43). 
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56: 3-Oxo-N,2-dipropylisoindoline-1-carboxamide: A solution of 3-oxo-2-
propylisoindoline-1-carboxylic acid (47.5 mg, 0.216 mmol) in dry THF (1.55 mL) was 
chilled to 0 ⁰C. CDI (38.6 mg, 0.238 mmol) was added and the reaction stirred for 2 h. 
Propylamine (27.0 μL, 0.325 mmol) was added and the reaction was allowed to reach 
rt. The progress of the reaction was followed by TLC (EtOAc-hexanes, 1:1).  When the 
starting material had been consumed, the reaction was quenched with aq. sat. NaHCO3 
and extracted with EtOAc (3 × 5 mL). The organic extracts were combined, dried over 
anhyd. Na2SO4, and concentrated by evaporation in vacuo to afford an oil.  56 was 
obtained by chromatography on silica gel, eluting with EtOAc-hexanes-triethylamine 
(50:50:1) as a clear oil (24.1 mg, 43%). 1H NMR (400 MHz, CDCl3) δ ppm 7.67 (t, J = 7.2 
Hz, 2H), 7.56 (t, J = 7.7 Hz, 1 H), 7.45 (t, J = 7.4 Hz, 1H), 6.23 (bs, 1H), 5.06 (s, 1H), 4.03-
3.96 (m, 1H), 3.30-3.21 (m, 1H), 3.16-3.10 (m, 2H) 1.74-1.62 (m, 2H), 1.50-1.41 (m, 2H), 
0.92 (t, J = 7.4, 3H), and 0.81 (t, J = 7.40, 3H). 13C NMR (100 MHz, CDCl3) δ ppm 169.59, 
167.87, 141.24, 132.24, 130.84, 128.99, 123.64, 122.74, 64.56, 43.43, 41.26, 22.58, 
21.29, 11.28, and 11.14.   HRMS (ESI-TOF) m/z calcd. for C15H21N2O2: 261.1598; found 
261.1594 ([M + H]+, ∆ ppm 1.44). 
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57: N-(2-(1H-indol-3-yl)ethyl)-2-benzyl-3-oxoisoindoline-1-carboxamide: A solution of 2-
benzyl-3-oxo-2,3-dihydro-1H-isonide-1-carboxylic acid (47.4 mg, 0.177 mmol) in dry 
THF (1.28 mL) was chilled to 0 ⁰C. CDI (31.6 mg, 0.195 mmol) was added and the 
reaction stirred for 2 h.  Tryptamine (42.6 mg, 0.266 mmol) was added and the reaction 
was allowed to reach rt.  The progress of the reaction was followed by TLC (EtOAc-
hexanes, 1:1).  When the starting material had been consumed, the reaction was 
quenched with aq. sat. NaHCO3 and extracted with EtOAc (3 × 5 mL). The organic 
extracts were combined, dried over anhyd. Na2SO4, and concentrated by evaporation 
in vacuo to afford a brown oil.  57 was obtained by chromatography on silica gel, 
eluting with EtOAc-hexanes-triethylamine (75:25:1) as a clear oil (10.3 mg, 21.8%).1H 
NMR (400 MHz, CDCl3) δ ppm 8.08 (s, 2H), 7.81 (d, J = 7.4 Hz, 2 H), 7.58-7.47 (m, 10 H), 
7.35 (d, J = 8.2, 1H), 7.24-7.19 (m, 9H), 7.13-7.09 (m, 6H), 6.71 (d, J = 2.0 Hz, 2H), 5.97 
(t, J = 5.7 Hz, 2H) 5.12 (d, J = 14.9 Hz, 2H), 4.79 (s, 2H), 4.13 (q,  J= 7.2 Hz, 1H), 3.94 (d,  
J= 14.8 Hz, 2H), 3.58-3.45 (m, 5H), 2.95-2.76 (m, 5H), 2.06 (s, 2H), 1.27 (t, J = 7.2 Hz, 4H) 
and 0.95-0.89 (m, 1H). 13C NMR (100 MHz, CDCl3) δ ppm 169.51, 167.39, 141.33, 
136.37, 136.04, 132.45, 130.50, 129.06, 128.89, 128.33, 127.95, 127.00, 123.94, 
122.89, 122.33, 121.95, 119.62, 118.50, 112.24, 111.32, 64.00, 60.38, 45.52, 39.40, 
24.83 and 21.04.  HRMS (ESI-TOF) m/z calcd. for C26H24N3O2: 410.1863; found 410.1853 
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([M + H]+, ∆ ppm 2.38). 
 
58: 2-Benzyl-N-(3-fluorobenzyl)-3-oxoisoindoline-1-carboxamide:  A solution of 2-benzyl-
3-oxoisoindoline-1-carboxylic acid (86.9 mg, 0.325 mmol) in dry THF (2.34 mL) was 
chilled to 0 ⁰C. CDI (58.0 mg, 0.358 mmol) was added and the reaction stirred for 2 h.  
3-flurobenzylamine (55.6 μL, 0.488 mmol) was added and the reaction was allowed to 
reach rt.  The progress of the reaction was followed by TLC (EtOAc-hexanes, 3:2).  
When the starting material had been consumed, the reaction was quenched with aq. 
sat. NaHCO3 and extracted with EtOAc (3 × 5 mL). The organic extracts were combined, 
dried over anhyd. Na2SO4, and concentrated by evaporation in vacuo to afford a brown 
oil.  58 was obtained by chromatography on silica gel, eluting with EtOAc-hexanes-
triethylamine (60:40:1) as a clear oil (42.3 mg, 34.8%). 1H NMR (400 MHz, CDCl3) δ ppm 
7.53 (d, J = 7.5 Hz, 1H), 7.45 (td, J = 6.9 Hz, 1.38 Hz, 1H) 7.35-7.25 (m, 4H), 7.24-7.17 
(m,2H), 7.15-7.09 (m, 3H), 6.84 (dd, J = 79 Hz, 1.76 Hz, 2 H) 6.76 (dt, J = 9.5 Hz, 1.9 Hz, 
1H), 5.16 (d, J = 14.9 Hz, 1H), 4.83 (s, 1H), 4.33 (d, J = 6.0 Hz, 2H), and 4.13 (d, J = 14.9 
Hz, 1H). 13C NMR (100 MHz, CDCl3) δ ppm  169.57, 167.77164.09, 161.64, 141.12, 
140.53, 140.46, 135.87, 132.43, 130.40, 130.13, 130.04, 129.6, 128.97, 128.41, 128.08, 
123.71, 123.19, 122.77, 114.63, 114.48, 114.41, 114.27, 64.16, 45.79, and 42.83.  
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HRMS (ESI-TOF) m/z calcd. for C23H20FN2O2: 375.1504; found 375.1508 ([M + H]
+, ∆ 
ppm 1.13). 
59: N-Isopropyl-2-(3-methylbenzyl)-3-oxoisoindoline-1-carboxamide: A solution of 2-(3-
methyl-benzyl)-3-oxo-2,3-dihydro-1H-isonide-1-carboxylic acid (91.2 mg, 0.320 mmol) 
in dry THF (2.32 mL) was chilled to 0 ⁰C. CDI (57.8 mg, 0.360 mmol) was added and the 
reaction stirred for 2 h.  Isopropylamine (39 μL, 0.48mmol) was added and the reaction 
was allowed to reach rt.  The progress of the reaction was followed by TLC (EtOAc-
hexanes, 1:1).  When the starting material had been consumed, the reaction was 
quenched with aq. sat. NaHCO3 and extracted with EtOAc (3 × 5 mL). The organic 
extracts were combined, dried over anhyd. Na2SO4, and concentrated by evaporation 
in vacuo to afford a brown oil.  59 was obtained by chromatography on silica gel, 
eluting with EtOAc-hexanes-triethylamine (75:25:1) as a clear oil (10.3 mg, 17.2%). 1H 
NMR (400 MHz, CDCl3) δ ppm 7.77 (d, J = 7.5 Hz, 1H), 7.62 (d, J = 7.5 Hz, 1H), 7.55 (t, J = 
7.4 Hz, 1H), 7.47 (t, J = 7.3 Hz, 1H), 7.21 (t, J = 7.5 Hz, 1H), 7.11 (d, J = 4.5 Hz, 2H), 7.09 
(bs, 1H), 5.91 (d, J = 7.5 Hz, 1H), 5.16 (d, J = 14.7 Hz, 1H), 4.84 (s, 1H), 4.32 (d, J = 14.7 
Hz, 1H), 3.96 - 4.05 (m, 1H), 2.31 (s, 3H), 1.07 (d, J = 6.53 Hz, 3H), and 0.91 - 0.96 (m, 
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3H). 13C NMR (100 MHz, CDCl3) δ ppm 169.8, 166.6, 141.5, 138.8, 136.3, 132.4, 130.5, 
129.2, 129.0, 128.9, 128.8, 125.6, 123.9, 122.7, 64.5, 46.1, 41.6, 22.3, 22.1, and 21.3.  
HRMS (ESI-TOF) m/z calcd. for C20H23N2O2: 323.1754; found 323.1752 ([M + H]
+, ∆ ppm 
0.54). 
 
60: 2-Cyclohexyl-N-isopropyl-3-oxoisoindoline-1-carboxamide: A solution of 2-cyclohexyl-
3-oxo-2,3-dihydro-1H-isoindole-1-carboxylic acid (62.3 mg, 0.240 mmol) in dry THF 
(2.73 mL) was chilled to 0 ⁰C. CDI (43.3 mg, 0.267 mmol) was added and the reaction 
stirred for 2 h.  Isopropyl amine (30.0 μL, 0.360 mmol) was added and the reaction was 
allowed to reach rt.  The progress of the reaction was followed by TLC (EtOAc-hexanes, 
1:1).  When the starting material had been consumed, the reaction was quenched with 
aq. sat. NaHCO3 and extracted with EtOAc (3 × 5 mL). The organic extracts were 
combined, dried over anhyd. Na2SO4, and concentrated by evaporation in vacuo to 
afford a brown oil.  60 was obtained by chromatography on silica gel, eluting with 
EtOAc-hexanes-triethylamine (50:50:1) as a clear oil (8.0 mg, 11.1%). 1H NMR (400 
MHz, CDCl3) δ ppm 7.76 (d, J = 7.5 Hz, 1H), 7.61 (d,  J= 7.4 Hz, 1 H), 7.56 (t, J = 7.3 Hz, 
1H), 7.48 (t, J =7.5,1H), 5.69 (d,  J = 7.9 Hz, 1H), 5.05 (s, 1H), 4.15-3.98 (m, 2H), 2.0 (d, J 
= 11.9 Hz,1H) 1.88-1.80 (m, 3H), 1.71-1.55 (m, 4H), 1.45-1.34 (m, 2H), 1.13 (d, J = 6.7 
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Hz, 3H), and 0.92 (d, J = 6.7Hz, 3H). 13C NMR (100 MHz, CDCl3) δ ppm 170.14, 167.97, 
141.73, 132.02, 130.85, 128.62, 123.41, 122.08, 63.23, 53.54, 41.32, 30.62, 30.55, 
25.51, 25.39, 24.92, and 21.82.   HRMS (ESI-TOF) m/z calcd. for C18H25N2O2: 301.1911; 
found 301.1918 ([M + H]+, ∆ ppm 2.40). 
 
61: 2-Cyclohexyl-3-oxo-N-propylisoindoline-1-carboxamide: A solution of 2-cyclohexyl-3-
oxoisoindoline-1-carboxylic acid (76.3 mg, 0.294 mmol) in dry THF (2.12 mL) was chilled 
to 0 ⁰C. CDI (56.0 mg, 0.323 mmol) was added and the reaction stirred for 2 h.  
Propylamine (26.1 mg, 0.441 mmol) was added and the reaction was allowed to reach 
rt.  The progress of the reaction was followed by TLC (EtOAc-hexanes, 1:1).  When the 
starting material had been consumed, the reaction was quenched with aq. sat. NaHCO3 
and extracted with EtOAc (3 × 5 mL). The organic extracts were combined, dried over 
anhyd. Na2SO4, and concentrated by evaporation in vacuo to afford a brown oil.  61 
was obtained by chromatography on silica gel, eluting with EtOAc-hexanes-
triethylamine (75:25:1) as a clear oil (22.2 mg, 25%). 1H NMR (400 MHz, CDCl3) δ ppm 
7.60 (d, J = 7.8 Hz, 1H), 7.63 (d, J = 7.5 Hz, 1H), 7.53 (t, J = 7.3 Hz, 1H), 7.42 (t, J = 7.4 Hz, 
1H), 6.28 - 6.37 (m, 1H), 5.07 (s, 1H), 4.07 (tt, J = 3.5, 12.1 Hz, 1H), 3.06 - 3.24 (m, 2H), 
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1.98 - 2.08 (m, 1H), 1.75 - 1.90 (m, 3H), 1.53 - 1.72 (m, 4H), 1.29 - 1.49 (m, 5H), 1.09 - 
1.27 (m, 2H), and 0.78 (t, J = 7.4 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ ppm 170.3, 169.3, 
141.5, 132.2, 131.2, 128.8, 123.5, 122.4, 63.6, 53.8, 41.2, 30.8, 30.8, 25.8, 25.7, 25.2, 
22.5, and 11.2.   HRMS (ESI-TOF) m/z calcd. for C18H25N2O2: 301.1911; found 301.1916 
([M + H]+, ∆ ppm 1.74). 
 
62: 2-Cyclohexyl-N-(2-morpholinoethyl)-3-oxoisoindoline-1-carboxamide: A solution of 2-
cyclohexyl-3-oxo-2,3-dihydro-1H-isoindole-1-carboxylic acid (76.8 mg, 0.296 mmol) in 
dry THF (3.50 mL) was chilled to 0 ⁰C. CDI (54.7 mg, 0.337 mmol) was added and the 
reaction stirred for 2 h.  4-(2-aminoethyl) morpholine (58.6 mg, 0.450 mmol)) was 
added and the reaction was allowed to reach rt.  The progress of the reaction was 
followed by TLC (EtOAc-hexanes, 1:1).  When the starting material had been 
consumed, the reaction was quenched with aq. sat. NaHCO3 and extracted with EtOAc 
(3 × 5 mL). The organic extracts were combined, dried over anhyd. Na2SO4, and 
concentrated by evaporation in vacuo to afford a brown oil.  62 was obtained by 
chromatography on silica gel, eluting with EtOAc-hexanes-triethylamine (60:40:1) to 
MeOH-EtOAc (10:90) as a yellow oil (24.6 mg, 22.4%). 1H NMR (400 MHz, CDCl3) δ ppm 
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7.70 (d, J = 7.4 Hz, 1H), 7.59 (d, J = 7.7 Hz, 1 H), 7.52 (t, J = 7.4 Hz, 1H), 7.42 (t, J = 7.3 
Hz, 1H), 6.56 (s,1H), 5.05 (s, 1H), 5.05 (s, 1H), 4.07-3.99 (m,2H) 3.69-3.61 (m, 2H), 3.55 
(t, J = 4.1 Hz, 4H), 3.41-3.34 (m, 1H), 3.19-3.11 (m,1H), 2.52-2.25 (m, 9H), 2.05 (d, J = 
11.8 Hz, 1H), 1.81 (d, J = 12.67 Hz, 4H), 1.72-1.54 (m,4H), 1.41-1.28 (m, 3H), and 1.23-
1.10 (m, 2H). 13C NMR (100 MHz, CDCl3) δ ppm 170.13, 169.19, 141.91, 132.09, 131.29, 
128.82, 123.52, 122.46, 66.61, 63.50, 56.55, 53.93, 53.12, 35.68, 30.70, 30.66, 25.79, 
25.72, and 25.19.  HRMS (ESI-TOF) m/z calcd. for C21H30N3O3: 372.2282; found 
372.2267 ([M + H]+, ∆ ppm 3.97). 
63: N,2-Dicyclohexyl-3-oxoisoindoline-1-carboxamide: A solution of 2-cyclohexyl-3-oxo-
2,3-dihydro-1H-isoindole-1-carboxylic acid (76.7 mg, 0.296 mmol) in dry THF (1.5 mL) 
was chilled to 0 ⁰C. CDI (53.6 mg, 0.331 mmol) was added and the reaction stirred for 2 
h.  Cyclohexylamine (51.0 μL, 0.444 mmol) was added and the reaction was allowed to 
reach rt.  The progress of the reaction was followed by TLC (EtOAc-hexanes, 1:1).  
When the starting material had been consumed, the reaction was quenched with aq. 
sat. NaHCO3 and extracted with EtOAc (3 × 5 mL). The organic extracts were combined, 
dried over anhyd. Na2SO4, and concentrated by evaporation in vacuo to afford a brown 
oil.  63 was obtained by chromatography on silica gel, eluting with EtOAc-hexanes-
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triethylamine (40:60:1) as a clear oil (6.2 mg, 6.2%). 1H NMR (400 MHz, CDCl3) δ ppm 
7.80 (d, J = 7.4 Hz, 1H), 7.61 (d, J = 7.3 Hz, 1 H), 7.55 (t, J = 7.5 Hz, 1H), 7.48 (t, J = 
7.4,1H), 5.64 (d, J = 8.0, 1H), 5.05 (s, 1H), 4.15-4.07 (m, 2H), 3.75-3.65 (m,1H) 2.01-1.80 
(m, 8H), 1.71-1.57 (m, 11H), 1.45-1.03 (m, 14H), and 0.98-0.77 (m, 2H).  13C NMR (100 
MHz, CDCl3) δ ppm 170.49, 168.23, 142.12, 132.35, 131.16, 128.95, 123.74, 122.40, 
63.64, 53.93, 48.53, 33.96, 32.67, 32.58, 30.98, 30.88, 25.83, 25.73, 25.26, 24.85, and 
24.68.  
 
64: N-(2-(1H-indol-3-yl)ethyl)-2-cyclohexyl-3-oxoisoindoline-1-carboxamide: A solution of 
2-cyclohexyl-3-oxo-2,3-dihydro-1H-isoindole-1-carboxylic acid (72.5 mg, 0.280 mmol) in 
dry THF (1.5 mL) was chilled to 0 ⁰C. CDI (67.2 mg, 0.414 mmol) was added and the 
reaction stirred for 2 h.  Tryptamine (67.1 mg, 0.419 mmol) was added and the reaction 
was allowed to reach rt.  The progress of the reaction was followed by TLC (EtOAc-
hexanes, 1:1).  When the starting material had been consumed, the reaction was 
quenched with aq. sat. NaHCO3 and extracted with EtOAc (3 × 5 mL). The organic 
extracts were combined, dried over anhyd. Na2SO4, and concentrated by evaporation 
in vacuo to afford a brown oil.  64 was obtained by chromatography on silica gel, 
eluting with EtOAc-hexanes-triethylamine (60:40:1) to (100:0:1) as a white solid (38.4 
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mg, 34.2%). 1H NMR (400 MHz, CDCl3) δ ppm 8.26 (bs, 1H), 7.65-7.56 (m, 2H), 7.49-7.39 
(m, 3H), 7.35 (d, J = 8.0 Hz, 2H), 7.19 ( t, J = 7.0 Hz, 1H), 7.12 (t, J =7.1 Hz, 1H), 7.04 (s, 
1H) 6.69-6.54 (m, 2H), 3.72 (t, J = 6.2 Hz, 2H), 3.05 (t, J = 6.5 Hz, 2H), 1.98-1.88 (m, 3H), 
1.77-1.66 (m, 3H), 1.65-1.54 (m, 3H), 1.35 (t, J = 13.6 Hz, 4H), 1.29-1.12 (m, 7H), and 
0.97-0.84 (m, 2H). 13C NMR (100 MHz, CDCl3) δ ppm 169.40, 168.08,136.37, 134.81, 
132.41, 130.03, 128.42, 127.97, 127.15, 122.22, 122.11, 119.40, 118.61, 112.49, 
111.25, 48.95, 40.34, 36.61, 32.74, 25.43, 25.15, and 24.67.  
 
65: N-Benzyl-2-cyclohexyl-3-oxoisoindoline-1-carboxamide: A solution of 2-cyclohexyl-3-
oxo-2,3-dihydro-1H-isoindole-1-carboxylic acid (76.5 mg, 0.256 mmol) in dry THF (1.5 
mL) was chilled to 0 ⁰C. CDI (57.0mg, 0.324 mmol) was added and the reaction stirred 
for 2 h.  Benzylamine (42.0 μL, 0.384 mmol) was added and the reaction was allowed to 
reach rt.  The progress of the reaction was followed by TLC (EtOAc-hexanes, 1:1).  
When the starting material had been consumed, the reaction was quenched with aq. 
sat. NaHCO3 and extracted with EtOAc (3 × 5 mL). The organic extracts were combined, 
dried over anhyd. Na2SO4, and concentrated by evaporation in vacuo to afford a brown 
oil.  65 was obtained by chromatography on silica gel, eluting with EtOAc-hexanes-
triethylamine (50:50:1) as an oil (2.9 mg, 2.8%).  1H NMR (400 MHz, CDCl3) δ ppm 7.64 
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(d, J = 7.5 Hz 1H), 7.57 (t, J = 7.4 Hz, 1H), 7.54-7.45 (m, 2H), 7.40-7.31 (m, 1H), 7.26-7.22 
(m, 2H), 7.10-7.05 (m, 2H), 6.22 (bs, 1H), 5.13 (s, 1H), 4.46, (dd, J = 14.6, 6.3 Hz, 1H), 
4.27 (dd, J = 14.6, 5.5 Hz, 1H), 1.98-1.55 (m, 10 H), and 1.54-1.02 (m, 11H). 13C NMR 
(100 MHz, CDCl3) δ ppm 170.29,169.10, 141.79, 137.20, 132.33, 131.27, 129.08, 
128.65, 127.78, 123.82, 122.55, 63.55, 53.85, 43.47, 30.82, 25.68, and 25.18.  HRMS 
(ESI-TOF) m/z calcd. for C22H25N2O2: 349.1911; found 349.1908 ([M + H]
+, ∆ ppm 0.79). 
 
66: 2-(2-(1H-indol-2-yl)ethyl)-3-oxo-N-propylisoindoline-1-carboxamide: A solution of 2-
(2-(1H-indol-3-yl)ethyl)-3-oxoisoindoline-1-carboxylic acid (75.0 mg, 0.250 mmol) in dry 
THF (1.5 mL) was chilled to 0 ⁰C. CDI (43.0 mg, 0.270 mmol) was added and the 
reaction stirred for 2 h.  Propylamine (22.2 mg, 0.377 mmol) was added and the 
reaction was allowed to reach rt.  The progress of the reaction was followed by TLC 
(EtOAc-hexanes, 1:1).  When the starting material had been consumed, the reaction 
was quenched with aq. sat. NaHCO3 and extracted with EtOAc (3 × 5 mL). The organic 
extracts were combined, dried over anhyd. Na2SO4, and concentrated by evaporation 
in vacuo to afford a brown oil.  66 was obtained by chromatography on silica gel, 
eluting with EtOAc-hexanes-triethylamine (75:25:1) as a clear oil (21.2 mg, 24.9%).  1H 
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NMR (400 MHz, CD3OD) δ ppm 7.79 (d, J = 7.4 Hz, 1H), 7.45 - 7.62 (m, 4H), 7.32 (d, J = 
8.2 Hz, 1H), 7.04 - 7.10 (m, 2H), 6.96 (d, J = 7.2 Hz, 1H), 4.32 (ddd, J = 6.2, 7.9, 14.0 Hz, 
1H), 3.38 - 3.46 (m, 1H), 3.03 - 3.24 (m, 5H), 1.43 - 1.54 (m, 2H), and 0.89 (t, J = 7.4 Hz, 
4H). 13C NMR (100 MHz, CD3OD) δ ppm 171.5, 169.8, 143.0, 138.4, 133.4, 133.1, 130.3, 
128.7, 124.5, 123.7, 123.4, 122.6, 119.9, 119.3, 112.9, 112.5, 43.9, 42.6, 25.2, 23.7, and 
11.8. 
 
67: N,2-Bis(4-isopropylbenzyl)-3-oxoisoindoline-1-carboxamide: A solution of 50 (2.1g, 
7.1mmol) in MeOH (40 mL) was stirred at rt for 5 minutes. 4-isopropylbenzylamine 
(5.7mL, 36 mmol) was added slowly over 10 minutes and the progress of the reaction 
was followed by TLC (EtOAc-hexanes, 30:70). When 50 was consumed the reaction was 
concentrated in vacuo followed by diluting with 1.2 M HCl and extracting with DCM (3 
x 20mL). The organic extracts were combined, dried over anhyd. Na2SO4, and 
concentrated by evaporation in vacuo to afford an orange oil.  67 was obtained by 
chromatography on silica gel, eluting with EtOAc-hexanes-glacial acetic acid (15:85:1) 
as a yellow oil (75 mg, 24%). 1H NMR (400 MHz, (CD3)2SO) δ ppm 7.62 (d, J = 8.4 Hz, 
2H), 7.54 (t, J = 7.4 Hz, 1H), 7.42 (t, J = 7.5 Hz, 1H), 7.16 (s, 4H), 7.14 (d, J = 8.2 Hz, 2H), 
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7.05 (d, J = 8.2 Hz, 2H), 6.59 (t, J = 5.7 Hz, 1H), 5.25 (d, J = 14.7 Hz, 1H), 4.91 (s, 1H), 
4.40-4.29 (m, 2H), 4.17 (d, J = 14.7 Hz, 1H), 2.91-2.84 (m, 2H), 1.22 (d, J = 6.9 Hz, 12H). 
13C NMR (100 MHz, (CD3)2SO) δ ppm 169.51, 167.51, 148.77, 148.40, 141.19, 134.82, 
133.31, 132.33, 130.59, 129.01, 128.60, 127.68, 127.01, 126.75, 123.92, 122.79, 63.97, 
45.51, 43.25, 33.76, and 23.93.   
68: 2-(2-(1H-indol-2-yl)ethyl)-3-oxoisoindoline-1-carboxylic acid: A solution of methyl 2-
(2-(1H-indol-2-yl)ethyl)-3-oxoisoindoline-1-carboxylate (399.0 mg, 1.2 mmol) in a 30 ml 
solution of a LiOH (2.5M aq), MeOH, THF (1:2:3 ratio) was stirred at rt and followed by 
TLC (EtOAc-hexanes, 1:1).  Once the starting material had been consumed, the reaction 
was quenched with an acid/base workup. The organic extracts were combined, dried 
over anhyd. Na2SO4, and concentrated by evaporation in vacuo to afford a brown oil.  
Dissolving the oil in chloroform and concentrating in vacuo afforded compound 68 as a 
yellow oil (253.8 mg, 66.4%). 1H NMR (400 MHz, (CD3)2SO) δ ppm 10.82 (s, 1H), 7.72 (d, 
J = 7.5 Hz, 1H), 7.63 (d, J = 3.9 Hz, 2H), 7.56 (dd, J = 7.5, 3.5 Hz, 2H) 7.33 (d, J = 8.0 Hz, 
1H), 7.18 (d, J = 2.1 Hz, 1H), 7.07 (t, J = 7.7 Hz, 1H), 6.97 (t, J = 7.0 Hz, 1H), 5.35 (s, 1H), 
4.22-4.12 (m, 1H) 3.50-3.41 (m, 1H), and 3.15-2.93 (m, 2H). 13C NMR (100 MHz, 
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(CD3)2SO) δ ppm 169.74, 167.45, 140.13, 136.22, 131.92, 131.55, 129.01, 127.02, 
122.91, 120.99, 118.29, 118.09, 111.43, 111.16, 62.07, 41.74, and 23.56.  HRMS (ESI-
TOF) m/z calcd. for C19H17N2O3: 321.1234; found 321.1242 ([M + H]
+, ∆ 2.57). 
69: 3-Oxo-2-propylisoindoline-1-carboxylic acid: A solution of methyl 3-oxo-2-
propylisoindoline-1-carboxylate (148.4 mg, 0.6361 mmol) in a 12 ml solution of a LiOH 
(2.5M aq), MeOH, THF (1:2:3 ratio) was stirred at rt and followed by TLC (EtOAc-
hexanes, 1:1).  Once the starting material had been consumed, the reaction was 
quenched with 2M HCl (25 mL) and extracted EtOAc (3 X 25 mL). The organic extracts 
were combined, dried over anhyd. Na2SO4, and concentrated by evaporation in vacuo 
to afford a brown oil.  69 was obtained by chromatography on silica gel, eluting with 
EtOAc-hexanes-glacial acetic acid (75:25:1) to (100:0:1) as a yellow solid (86.7 mg, 
62.2%). 1H NMR (400 MHz, CD3OD) δ ppm 7.74 (d, J = 7.5 Hz, 1H), 7.69 (d, J = 7.7 Hz, 
1H), 7.59 (t, J = 7.4 Hz, 1H), 7.51 (t, J = 7.4 Hz, 1H), 5.30 (s, 1H), 3.90 (sex, 2H), and 0.91 
(t, J = 7.4 Hz, 3H).    13C NMR (100 MHz, CD3OD) δ ppm 172.10, 143.22, 134.25, 133.79, 
131.14, 125.23, 125.06, 69.26, 45.43, 23.23, and 12.71. HRMS (ESI-TOF) m/z calcd. for 
C12H14NO3: 220.0968; found 220.0967 ([M + H]
+, ∆ ppm 1.17). 
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70: 2-Benzyl-3-oxoisoindoline-1-carboxylic acid: A solution of methyl 3-oxo-2-
propylisoindoline-1-carboxylate (148.4 mg, 0.6361 mmol) in a 12 ml solution of a LiOH 
(2.5M aq), MeOH, THF (1:2:3 ratio) was stirred at rt and followed by TLC (EtOAc-
hexanes, 1:1).  Once the starting material had been consumed, the reaction was 
quenched with 2M HCl (25 mL) and extracted EtOAc (3 X 25 mL). The organic extracts 
were combined, dried over anhyd. Na2SO4, and concentrated by evaporation in vacuo 
to afford a brown oil.  69 was obtained by chromatography on silica gel, eluting with 
EtOAc-hexanes-glacial acetic acid (75:25:1) to (100:0:1) as a yellow solid (86.7 mg, 
62.2%). 1H NMR (400 MHz, CD3OD) δ ppm 7.74 (d, J = 7.5 Hz, 1H), 7.69 (d, J = 7.7 Hz, 
1H), 7.59 (t, J = 7.4 Hz, 1H), 7.51 (t, J = 7.4 Hz, 1H), 5.30 (s, 1H), 3.90 (sex, 2H), and 0.91 
(t, J = 7.4 Hz, 3H).    13C NMR (100 MHz, CD3OD) δ ppm 172.10, 143.22, 134.25, 133.79, 
131.14, 125.23, 125.06, 69.26, 45.43, 23.23, and 12.71.  HRMS (ESI-TOF) m/z calcd. for 
C16H14NO3: 268.0968; found 268.0968 ([M + H]
+, ∆ ppm 0.00). 
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71: 2-(4-(Tert-butyl)benzyl)-3-oxoisoindoline-1-carboxylic acid: A solution of methyl 2-(4-
(tert-butyl)benzyl)-3-oxoisoindoline-1-carboxylate (1.03 mg, 3.05 mmol) in MeOH/THF 
(2:3, 100 mL) was stirred at room temperature for 5 minutes. 2.5M LiOH (20 mL) was 
added and the reaction progress was followed by TLC (EtOAc-hexanes, 1:1).  Once the 
starting material had been consumed, the reaction was quenched with 2M HCl (25 mL) 
and extracted EtOAc (3 X 25 mL). The organic extracts were combined, dried over 
anhyd. Na2SO4, extracted with EtOAc (3 × 15 mL). The aqueous extracts were combined 
and acidified using 2M HCl and extracted with EtOAc (3 × 15 mL), the organic extracts 
were combined, dried over Na2SO4, and concentrated by evaporation in vacuo to 
afford 71 as a white solid )160 mg, 16.2%). 1H NMR (400 MHz, CD3OD) δ ppm 7.83 (d, J 
= 7.3 Hz, 1H), 7.53 - 7.69 (m, 1H), 7.40 (d, J = 8.5 Hz, 2H), 7.21 (s, 2H), 5.36 (d, J = 15.3 
Hz, 1H), 4.95 (s, 1H), 4.91 - 4.99 (m, 1H), 4.28 (d, J = 15.1 Hz, 1H), and 1.29 (s, 9H) 13C 
NMR (100 MHz, CD3OD) δ  ppm 171.2, 170.9, 141.5, 134.7, 133.5, 132.6, 130.6, 130.1, 
129.4, 127.1, 124.7, 124.4, 63.3, 45.7, 35.4, and 31.9. 
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76: Isobutyl (2-isocyano-2-methylpropyl) carbonate: A solution of 4,4-dimethyl-2-
oxazoline (5 mL, 47.4 mmol), 74, in THF (48 mL) was cooled to -78 ⁰C in a dry 
ice/acetone bath.  N-butyl lithium (20 mL, 49.8 mmol) was added drop wise and stirred 
for 1 h.  Ethyl chloroformate (4.80 mL, 50.1 mmol), 75, was added and the reaction 
progress was followed by TLC (EtOAc-hexanes, 1:1).  Once the starting material had 
been consumed, the reaction was quenched with DI H2O, washed with brine, and 
extracted with EtOAc. The organic extracts were combined, dried over anhyd. Na2SO4, 
and concentrated by evaporation in vacuo to afford a brown oil.  76 was obtained by 
chromatography on silica gel, eluting with EtOAc-hexanes (10 - 50% gradient). 76 was 
isolated as a clear oil (5.167 g, 64%). 1H NMR (400 MHz, CDCl3) δ ppm 4.22, (q, J = 7.1 
Hz, 2H), 4.07 (t, J = 1.9 Hz, 2H), 1.45 (t, J = 1.9 Hz, 6H), and 1.31 (t, J = 7.2 Hz, 3H).  13C 
NMR (100 MHz, CDCl3) δ ppm 154.54, 72.31, 64.46, 56.13, 25.69, and 14.07.   This 
known compound was synthesized following the procedure outlined by Ugi et al.125  
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77: 2-(2-(4-(Tert-butyl)benzyl)-5-hydroxy-3-oxo-4-(4-(trifluoromethyl)phenyl)isoindoline-
1-carboxamido)-2-methylpropyl isobutyl carbonate: 4-tert-butyl-benzylamine (1.05 
mL, 6.0 mmol) and furfural (0.50 mL, 6.0 mmol) were combined in methanol (6 mL) and 
stirred at ambient temperature for 20 minutes.  Next, a solution of 3-(4-
(trifluoromethyl)phenyl)propiolic acid (1.28 g,  6.0 mmol) in methanol (3 mL) was 
added and stirred for 5 minutes.  Next, isobutyl (2-isocyano-2-methylpropyl) carbonate 
(1.23 g, 6.0 mmol) was added.  The reaction flask was then wrapped in foil and stirred 
at ambient temperature.  After 2.5 h, the reaction mixture was concentrated under 
reduced pressure to near dryness.  The crude product was purified by silica gel flash 
chromatography (10% EtOAc/hexanes - 30% EtOAc/hexanes) yielding a yellow-orange 
oil which was taken to the next step.  To the resultant yellow-orange oil was added 
dioxane (300 mL) and ytterbium (III) trifluoromethane sulfonate (0.74 g, 1.2 mmol) and 
stirred at 100°C.  After 11 hours, the reaction mixture was cooled to ambient 
temperature and filtered through Celite and concentrated.  The crude product was 
purified by silica gel flash chromatography (10% EtOAc/hexanes - 40% EtOAc/hexanes) 
yielding 2-(2-(4-(tert-butyl)benzyl)-5-hydroxy-3-oxo-4-(4-
(trifluoromethyl)phenyl)isoindoline-1-carboxamido)-2-methylpropyl isobutyl carbonate 
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(light-yellow solid, 1.60 g, 39.5%).  1H NMR (400 MHz, CDCl3) d 7.77 - 7.84 (d, J = 8.0 Hz, 
2H), 7.57 - 7.65 (d, J = 8.0 Hz, 2H), 7.49 (dd, J = 0.6, 8.4 Hz, 1H), 7.30 - 7.37 (m, 2H), 7.20 
- 7.26 (m, 2H), 7.18 (d, J = 8.3 Hz, 1H), 5.65 (s, 1H), 5.38 (s, 1H), 5.02 (d, J = 14.8 Hz, 1H), 
4.67 (s, 1H), 4.31 (d, J = 14.6 Hz, 1H), 4.18 (s, 2H), 3.88 (d, J= 6.8 Hz, 2H), 1.93 (m, 1H), 
1.29 (s, 9H), 1.23 (d, J = 3.0 Hz, 6H), and 0.92 (d, J = 6.8 Hz, 6H). 
 
 
 
78: 2-(4-(Tert-butyl)benzyl)-5-hydroxy-3-oxo-4-(4-(trifluoromethyl)phenyl)isoindoline-1-
carboxylic acid: A solution of 77 (315.0 mg, 0.50 mmol) in dry THF (1 mL) was stirred at 
rt for 5 minutes. A solution of tBuOK (121 mg, 1.01 mmol) in THF (0.5 mL) was added 
and stirred at ambient temperature for 1 h.  A solution of potassium carbonate (78.6 
mg, 0.57 mmol) in DI H2O (1.5 mL) was added and the progress of the reaction was 
followed by TLC (EtOAc-hexanes, 1:1).  Once done, the reaction was quenched with aq. 
HCl (1.2M) and extracted with EtOAc (3 x 5 mL).  The organic extracts where combined 
and washed with brine and dried over anhyd. Na2SO4. The solvent was removed by 
evaporation in vacuo to afford a brown oil.  78 was obtained by chromatography on 
silica gel gradient eluting with EtOAc-hexanes-1% glacial acetic acid (50:50:1 to 
98 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
100:0:1) as a yellow oil (85.0 mg, 35%). 1H NMR (400 MHz, CDCl3) δ ppm 11.97 (bs, 2H), 
9.89 (bs, 1H), 8.07 (s, 1H), 7.72 (d, J = 8.2 Hz, 2H), 7.54 (d, J = 7.9 Hz, 2H), 7.35 (d, J = 8.3 
Hz, 2H) 7.17 (d, J = 8.3 Hz, 1H), 7.12 (d, J = 8.2 Hz, 2H), 4.97 (d, J = 15.2 Hz, 1H), 4.89 (s, 
1H), 3.86 (d, J = 15.1 Hz, 1H), and 1.25 (s, 9H). 13C NMR (100 MHz, CDCl3) δ ppm 167.16, 
166.41, 154.91, 149.74, 134.12, 133.21, 131.57, 128.91, 127.75, 125.38, 123.92, 
123.72, 122.82, 119.16, 54.85, 34.18, and 31.10. 
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